XOLAIR® (omalizumab) IS INDICATED FOR add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

IMPORTANT SAFETY INFORMATION

WARNING: Anaphylaxis

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur.

NOW APPROVED FOR NASAL POLYPS

In adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment

Please see pages 10-11 and accompanying full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.
STUDY DESIGN FOR NASAL POLYPS TRIALS 1 AND 2

XOLAIR was studied in two randomized, multicenter, double-blind, placebo-controlled phase 3 pivotal trials that enrolled patients with nasal polyps with inadequate response to nasal corticosteroids.

Assessing the efficacy and safety of XOLAIR in two pivotal phase 3 trials

**AFTER run-in**
- NPS ≥5
- NCS >1
- No requirement for prior SCS or NP surgery

<table>
<thead>
<tr>
<th>Run-in: 5 weeks</th>
<th>Treatment period: 24 weeks</th>
<th>Safety follow-up/OLE: 4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen Randomization (1:1)</td>
<td>XOLAIR Q2W or Q4W*</td>
<td>Placebo Q2W or Q4W</td>
</tr>
</tbody>
</table>

**Background therapy: Nasal mometasone**

<table>
<thead>
<tr>
<th>Week: -5 -1 0 4 8 12 16 20 24 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal endoscopy assessment visit</td>
</tr>
</tbody>
</table>

Arrows indicate assessment visits.

*Administered XOLAIR 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks. Dosing based on weight and IgE up to a maximum of IgE 1500 IU/mL.

NPS was measured via endoscopy and scored (range 0-4 per nostril) for a total NPS (range 0/best-8/worst). Nasal congestion was measured by a daily NCS (range 0/best-3/worst). Patients were required to have NPS ≥5 and weekly average of NCS >1 prior to randomization, despite use of nasal mometasone. The mean NPS and NCS at baseline was balanced between the two treatment groups in both studies.

- In the clinical trials, 90.4% of patients in the XOLAIR group (n=122/135) were dosed Q4W and 9.6% (n=13/135) were dosed Q2W.
  - Median XOLAIR dose was 300 mg in patients treated Q4W and 450 mg in patients treated Q2W.

IgE=immunoglobulin E; NCS=nasal congestion score; NP=nasal polyp; NPS=nasal polyp score; OLE=open-label extension; Q2W=every 2 weeks; Q4W=every 4 weeks; SCS=systemic corticosteroid.

IMPORTANT SAFETY INFORMATION (cont’d)

CONTRAINDICATIONS

The use of XOLAIR is contraindicated in patients with a severe hypersensitivity reaction to XOLAIR or to any ingredient of XOLAIR.
Anaphylaxis
Anaphylaxis has been reported to occur after administration of XOLAIR in asthma premarketing clinical trials and in postmarketing spontaneous reports. The frequency of anaphylaxis attributed to XOLAIR use was estimated to be 0.1% and at least 0.2% (based on an estimated exposure of about 57,300 patients from June 2003 through December 2006), respectively.

A case-control study showed that among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis.

IgE=immunoglobulin E; IU=international units; NCS=nasal congestion score; NPS=nasal polyp score; SD=standard deviation.

IMPORTANT SAFETY INFORMATION (cont’d)
WARNINGS AND PRECAUTIONS

Parameter* | Nasal Polyps Trial 1 (n=138) | Nasal Polyps Trial 2 (n=127)
--- | --- | ---
Mean age (years) (SD) | 51 (13) | 50 (12)
% Male | 64 | 65
Patients with systemic corticosteroid use in the previous year (%) | 19 | 26
Patients with prior surgery for nasal polyps (%) | 79 (57) | 79 (62)
Mean bilateral endoscopic NPS (SD), range 0-8 | 6.2 (1.0) | 6.3 (0.9)
Mean NCS (SD), range 0-3 | 2.4 (0.6) | 2.3 (0.7)
Mean sense of smell score (SD), range 0-3 | 2.7 (0.7) | 2.7 (0.7)
Mean post-nasal drip score (SD), range 0-3 | 1.8 (0.9) | 1.7 (0.9)
Mean runny nose score (SD), range 0-3 | 2.0 (0.8) | 1.9 (0.9)
Mean blood eosinophils (cells/mcL) (SD) | 346 (284) | 335 (188)
Mean total IgE IU/mL (SD) | 161 (140) | 190 (201)
Asthma (%) | 54 | 61
Aspirin exacerbated respiratory disease (%) | 20 | 35

*For NPS, NCS, sense of smell, post-nasal drip, and runny nose, higher scores indicate greater disease severity.1

1Please see pages 10-11 and accompanying full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.
XOLAIR SIGNIFICANTLY REDUCED BOTH NASAL POLYP SIZE AND NASAL CONGESTION

In both Nasal Polyps Trials 1 and 2, patients who received XOLAIR had a statistically significant greater improvement from baseline at Week 24 in NPS and weekly average NCS than patients who received placebo.

<table>
<thead>
<tr>
<th>Change from baseline at Week 24 in NPS and 7-day average of daily NCS in Nasal Polyps Trials 1 and 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trial 1</strong></td>
</tr>
<tr>
<td>Placebo</td>
</tr>
<tr>
<td>Number of patients*</td>
</tr>
<tr>
<td><strong>Nasal Polyp Score</strong></td>
</tr>
<tr>
<td>Mean baseline score</td>
</tr>
<tr>
<td>LS mean change from baseline at Week 24</td>
</tr>
<tr>
<td>Difference in LS means vs placebo</td>
</tr>
<tr>
<td>95% CI for difference</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td><strong>7-day Average of Daily Nasal Congestion Score</strong></td>
</tr>
<tr>
<td>Mean baseline score</td>
</tr>
<tr>
<td>LS mean change from baseline at Week 24</td>
</tr>
<tr>
<td>Difference in LS means vs placebo</td>
</tr>
<tr>
<td>95% CI for difference</td>
</tr>
<tr>
<td>P value</td>
</tr>
</tbody>
</table>

*All patients received background nasal mometasone therapy.

CI=confidence interval; LS=least squares; NCS=nasal congestion score; NPS=nasal polyp score.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

Anaphylaxis (cont’d)

Observe patients closely for an appropriate period of time after administration of XOLAIR, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports. Anaphylaxis occurred with the first dose of XOLAIR in 2 patients and with the fourth dose in 1 patient; the time to onset of anaphylaxis was 90 minutes after administration in 2 patients and 2 hours after administration in 1 patient. Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction.
Malignancy
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of adults and adolescents (≥12 years of age) with asthma and other allergic disorders. The observed malignancies in XOLAIR-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The majority of patients were observed for less than 1 year. The impact of longer exposure to XOLAIR or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known.

LS=least squares; NCS=nasal congestion score; NPS=nasal polyp score; SE=standard error.
XOLAIR SIGNIFICANTLY IMPROVED SENSE OF SMELL, POST-NASAL DRIP, AND RUNNY NOSE

XOLAIR had statistically significant improvements on sense of smell, post-nasal drip, and runny nose scores compared to placebo at Week 24*.

<table>
<thead>
<tr>
<th>Sense of smell score</th>
<th>Trial 1</th>
<th>95% CI for difference</th>
<th>Trial 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difference in LS means vs placebo</td>
<td>-0.3</td>
<td>(-0.6, -0.1)</td>
<td>-0.5</td>
</tr>
<tr>
<td>Post-nasal drip score</td>
<td>95% CI for difference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference in LS means vs placebo</td>
<td>-0.6</td>
<td>(-0.8, -0.3)</td>
<td>-0.5</td>
</tr>
<tr>
<td>Runny nose score</td>
<td>95% CI for difference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference in LS means vs placebo</td>
<td>-0.4</td>
<td>(-0.7, -0.2)</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

*All patients received background nasal mometasone therapy.

CI=confidence interval; LS=least squares.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

Malignancy (cont’d)
A subsequent 5-year observational study of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated adolescent and adult patients with moderate to severe persistent asthma and a positive skin test reaction or in vitro reactivity to a perennial aeroallergen found that the incidence rates of primary malignancies (per 1000 patient years) were similar in both groups (12.3 vs 13.0, respectively). Study limitations which include the observational study design, the bias introduced by allowing enrollment of patients previously exposed to XOLAIR (88%), enrollment of patients (56%) while a history of cancer or a premalignant condition were study exclusion criteria, and the high study discontinuation rate (44%) preclude definitively ruling out a malignancy risk with XOLAIR.

Acute Asthma Symptoms
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus.
ADVERSE REACTIONS FROM NASAL POLYPS TRIALS 1 AND 2

The data described below reflect XOLAIR exposure for 135 patients ≥18 years of age, exposed for 6 months in two placebo-controlled studies. All patients received background nasal mometasone therapy throughout the study.

<table>
<thead>
<tr>
<th>Adverse reactions occurring in ≥3% of XOLAIR-treated patients and more frequently than in patients treated with placebo</th>
<th>XOLAIR n=135</th>
<th>Placebo n=130</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>4 (3.0%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reactions*</td>
<td>7 (5.2%)</td>
<td>2 (1.5%)</td>
</tr>
<tr>
<td>Musculoskeletal system and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>4 (3.0%)</td>
<td>2 (1.5%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>11 (8.1%)</td>
<td>7 (5.4%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4 (3.0%)</td>
<td>1 (0.8%)</td>
</tr>
</tbody>
</table>

*Injection site reactions terms: “injection site reaction,” “injection-related reaction,” and “injection site pain.” All of the injection site reactions were mild to moderate severity and none resulted in study discontinuation.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

Corticosteroid Reduction
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of XOLAIR therapy for asthma or nasal polyps. Decrease corticosteroids gradually under the direct supervision of a physician.

Eosinophilic Conditions
In rare cases, patients with asthma on therapy with XOLAIR may present with serious systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between XOLAIR and these underlying conditions has not been established.
Administer XOLAIR 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks*  
> Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL) measured before the start of treatment, and by body weight (kg)

<table>
<thead>
<tr>
<th>Pretreatment Serum IgE (IU/mL)</th>
<th>Dosing Freq.</th>
<th>Body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt;66-88 lb (&gt;30-40 kg)</td>
</tr>
<tr>
<td>30 - 100</td>
<td>Every 4 Weeks</td>
<td>75</td>
</tr>
<tr>
<td>&gt;100 - 200</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>&gt;200 - 300</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;300 - 400</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;400 - 500</td>
<td></td>
<td>450</td>
</tr>
<tr>
<td>&gt;500 - 600</td>
<td></td>
<td>450</td>
</tr>
<tr>
<td>&gt;600 - 700</td>
<td></td>
<td>450</td>
</tr>
<tr>
<td>&gt;700 - 800</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;800 - 900</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;900 - 1000</td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>&gt;1000 - 1100</td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>&gt;1100 - 1200</td>
<td></td>
<td>450</td>
</tr>
<tr>
<td>&gt;1200 - 1300</td>
<td></td>
<td>450</td>
</tr>
<tr>
<td>&gt;1300 - 1500</td>
<td></td>
<td>525</td>
</tr>
</tbody>
</table>

Note: Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.1

IgE=immunoglobulin E.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

Fever, Arthralgia, and Rash
In post-approval use, some patients have experienced a constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy with an onset 1 to 5 days after the first or subsequent injections of XOLAIR. These signs and symptoms have recurred after additional doses in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.
XOLAIR IS DESIGNED TO BLOCK IGE, A KEY DRIVER OF INFLAMMATION IN NASAL POLYPS\(^1,4\)

- Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and dendritic cells, resulting in FcεRI down-regulation on these cells\(^1\)
- In allergic asthmatics, treatment with omalizumab inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL-4, IL-5, and IL-13\(^1\)

Parasitic (Helmint) Infection
Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.

Laboratory Tests
Due to formation of XOLAIR:IgE complexes, serum total IgE levels increase following administration of XOLAIR and may remain elevated for up to 1 year following discontinuation of XOLAIR. Do not use serum total IgE levels obtained less than 1 year following discontinuation to reassess the dosing regimen for asthma or nasal polyps patients, because these levels may not reflect steady state free IgE levels.

ADVERSE REACTIONS

Indication-Specific Adverse Reactions

Asthma
In patients \(\geq 12\) years of age, the most common adverse reactions (\(\geq 1\%\) more frequent in XOLAIR-treated patients) were: arthralgia (8\%), pain (general) (7\%), leg pain (4\%), fatigue (3\%), dizziness (3\%), fracture (2\%), arm pain (2\%), pruritus (2\%), dermatitis (2\%), and earache (2\%). In pediatric patients 6 to \(<12\) years of age, the most commonly observed adverse reactions (\(\geq 3\%\) more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, and epistaxis.

IgE=immunoglobulin E; IL=interleukin.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

Parasitic (Helmint) Infection
Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.

Laboratory Tests
Due to formation of XOLAIR:IgE complexes, serum total IgE levels increase following administration of XOLAIR and may remain elevated for up to 1 year following discontinuation of XOLAIR. Do not use serum total IgE levels obtained less than 1 year following discontinuation to reassess the dosing regimen for asthma or nasal polyps patients, because these levels may not reflect steady state free IgE levels.

ADVERSE REACTIONS

Indication-Specific Adverse Reactions

Asthma
In patients \(\geq 12\) years of age, the most common adverse reactions (\(\geq 1\%\) more frequent in XOLAIR-treated patients) were: arthralgia (8\%), pain (general) (7\%), leg pain (4\%), fatigue (3\%), dizziness (3\%), fracture (2\%), arm pain (2\%), pruritus (2\%), dermatitis (2\%), and earache (2\%). In pediatric patients 6 to \(<12\) years of age, the most commonly observed adverse reactions (\(\geq 3\%\) more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, and epistaxis.
IMPORTANT SAFETY INFORMATION

INDICATION

XOLAIR® (omalizumab) IS INDICATED FOR

- Add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
- Moderate to severe persistent asthma in patients 6 years of age and older who have a positive skin test or in vitro reactivity to a perennial allergen and whose symptoms are inadequately controlled with inhaled corticosteroids. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.

Limitations of Use: XOLAIR is not indicated for the relief of acute bronchospasm, status asthmaticus, or for treatment of other allergic conditions.

CONTRAINDICATIONS

The use of XOLAIR is contraindicated in patients with a severe hypersensitivity reaction to XOLAIR or to any ingredient of XOLAIR.

WARNINGS AND PRECAUTIONS

Anaphylaxis

Anaphylaxis has been reported to occur after administration of XOLAIR in asthma premarketing clinical trials and in postmarketing spontaneous reports. The frequency of anaphylaxis attributed to XOLAIR use was estimated to be 0.1% and at least 0.2% (based on an estimated exposure of about 57,300 patients from June 2003 through December 2006), respectively.

A case-control study showed that among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis.

Observe patients closely for an appropriate period of time after administration of XOLAIR, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports. Anaphylaxis occurred with the first dose of XOLAIR in 2 patients and with the fourth dose in 1 patient; the time to onset of anaphylaxis was 90 minutes after administration in 2 patients and 2 hours after administration in 1 patient. Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction.

Malignancy

Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of adults and adolescents (≥12 years of age) with asthma and other allergic disorders. The observed malignancies in XOLAIR-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The majority of patients were observed for less than 1 year. The impact of longer exposure to XOLAIR or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known.

A subsequent 5-year observational study of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated adolescent and adult patients with moderate to severe persistent asthma and a positive skin test reaction or in vitro reactivity to a perennial allergen found that the incidence rates of primary malignancies (per 1000 patient years) were similar in both groups (12.3 vs 13.0, respectively). Study limitations which include the observational study design, the bias introduced by allowing enrollment of patients previously exposed to XOLAIR (88%), enrollment of patients (56%) while a history of cancer or a premalignant condition were study exclusion criteria, and the high study discontinuation rate (44%) preclude definitively ruling out a malignancy risk with XOLAIR.

Acute Asthma Symptoms

XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus.

Corticosteroid Reduction

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of XOLAIR therapy for asthma or nasal polyps. Decrease corticosteroids gradually under the direct supervision of a physician.

Eosinophilic Conditions

In rare cases, patients with asthma on therapy with XOLAIR may present with serious systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between XOLAIR and these underlying conditions has not been established.
Fever, Arthralgia, and Rash
In post-approval use, some patients have experienced a constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy with an onset 1 to 5 days after the first or subsequent injections of XOLAIR. These signs and symptoms have recurred after additional doses in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.

Parasitic (Helminth) Infection
Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.

Laboratory Tests
Due to formation of XOLAIR-IgE complexes, serum total IgE levels increase following administration of XOLAIR and may remain elevated for up to 1 year following discontinuation of XOLAIR. Do not use serum total IgE levels obtained less than 1 year following discontinuation to reassess the dosing regimen for asthma or nasal polyps patients, because these levels may not reflect steady state free IgE levels.

ADVERSE REACTIONS

Indication-Specific Adverse Reactions

Asthma
In patients ≥12 years of age, the most common adverse reactions (≥1% more frequent in XOLAIR-treated patients) were: arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). In pediatric patients 6 to <12 years of age, the most commonly observed adverse reactions (≥3% more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis, streptococcal, otitis media, viral gastroenteritis, arthropod bite, and epistaxis.

Nasal Polyps
The most common adverse reactions (≥3% incidence in XOLAIR-treated patients and more frequent than placebo) included: headache (8.1%), injection site reaction (5.2%), arthralgia (3.0%), upper abdominal pain (3.0%), and dizziness (3.0%).

Injection Site Reactions

Asthma
In adults and adolescents with asthma, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. Severe injection site reactions occurred more frequently in XOLAIR treated patients compared with patients in the placebo group (12% vs 9%, respectively). The types of injection site reactions in asthma studies included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.

Nasal Polyps
Injection site reactions occurred at a rate of 5.2% in XOLAIR-treated patients compared with 15% in placebo-treated patients. Injection site reactions were mild to moderate severity and none resulted in study discontinuation.

Cardiovascular and Cerebrovascular Events from Clinical Studies in Patients with Asthma
A 5-year observational study was conducted in 5007 XOLAIR-treated and 2829 non-XOLAIR-treated patients ≥12 years of age with moderate to severe persistent asthma and a positive skin test reaction to a perennial aeroallergen to evaluate the long term safety of XOLAIR, including the risk of malignancy. Similar percentages of patients in both cohorts were current (5%) or former smokers (29%). Patients had a mean age of 45 years and were followed for a mean of 3.7 years. More XOLAIR-treated patients were diagnosed with severe asthma (50%) compared to the non-XOLAIR-treated patients (23%). A higher incidence rate (per 1000 patient-years) of overall cardiovascular and cerebrovascular serious adverse events (SAEs) was observed in XOLAIR-treated patients (13.4) compared to non-XOLAIR-treated patients (8.1). Increases in rates were observed for transient ischemic attack (0.7 vs 0.1), myocardial infarction (2.1 vs 0.8), pulmonary hypertension (0.5 vs 0), pulmonary embolism/venous thrombosis (3.2 vs 1.5), and unstable angina (2.2 vs 1.4), while the rates observed for ischemic stroke and cardiovascular death were similar among both study cohorts. The results suggest a potential increased risk of serious cardiovascular and cerebrovascular events in patients treated with XOLAIR, however the observational study design, the inclusion of patients previously exposed to XOLAIR (88% for a mean of 8 months), baseline imbalances in cardiovascular risk factors between the treatment groups, an inability to adjust for unmeasured risk factors, and the high study discontinuation rate (44%) limit the ability to quantify the magnitude of the risk.

Pregnancy
Data with XOLAIR use in pregnant women are insufficient to inform on drug associated risk.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.

References:
COMMITTED TO HELPING PATIENTS GET THE TREATMENT THEY MAY NEED

XOLAIR Access Solutions provides coverage support:
• Benefits investigations, resources for prior authorization and denials/appeals
• My Patient Solutions is our online patient management tool

Help your patients pay for XOLAIR through our co-pay program*:
Eligible commercially insured patients pay:
• $5 per XOLAIR drug out-of-pocket cost. The program covers the rest up to $10,000 for each 12-month period
• $5 per XOLAIR administration out-of-pocket cost. The program covers the rest up to $1,000 for each 12-month period

Help your patients receive treatment, regardless of coverage:
• For eligible patients with commercial or public health insurance, XOLAIR Access Solutions offers referrals to independent co-pay assistance foundations
• Genentech Patient Foundation† gives eligible patients XOLAIR for free

• XOLAIR Sample Program
• XOLAIR Starter Program§

*In order to qualify for the benefits of the XOLAIR Administration Co-pay Program, the patient may be required to pay certain out-of-pocket expenses for each injection. Patients using Medicare, Medicaid, Medigap, Veteran’s Affairs (VA), Department of Defense (DoD), TriCare, or any other federal or state government funded program to pay for their medications are not eligible. Patients who start utilizing their government coverage during their enrollment period will no longer be eligible for the program. The XOLAIR Administration Co-pay Program is not valid for Massachusetts, Michigan, Minnesota, or Rhode Island residents. Once enrolled, the XOLAIR Administration Co-pay Program will not honor claims with date of service or medication dispensing that precede program enrollment by more than 120 days. Participating patients, physician offices, and hospitals are responsible for reporting the receipt of all XOLAIR Administration Co-pay Program benefits or reimbursement received, to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the XOLAIR Administration Co-pay Program. This program is not health insurance or a benefit plan. The patient or their guardian must be 18 years or older to receive XOLAIR Administration Co-pay Program benefits. This XOLAIR Administration Co-pay Program is void if the card is reproduced and where prohibited by law. It is only valid for injection with XOLAIR and only valid in the U.S. and U.S. Territories. The XOLAIR Administration Co-pay Program expires within 12 months from enrollment. Genentech, Inc. and Novartis Pharmaceuticals Corporation reserve the right to rescind, revoke, or amend the program without notice at any time. Patient, guardian, prescriber, hospital and any other person using or administering the XOLAIR Administration Co-pay Program agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer. Additional terms and conditions apply. Please visit XOLAIRcopay.com for the full list of terms and conditions.

†Genentech, Inc. and Novartis Pharmaceuticals Corporation do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from XOLAIR Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Novartis Pharmaceuticals Corporation’s endorsement or financial support. There may be other foundations to support the patient’s disease state.

‡ To be eligible for free XOLAIR from the Genentech Patient Foundation, insured patients must have exhausted all other forms of patient assistance (including the XOLAIR Co-pay Program and support from independent co-pay assistance foundations) and meet financial criteria. Uninsured patients must meet different financial criteria.

§To be eligible for the XOLAIR Starter Program, patients must have insurance and must meet other criteria.

Please see pages 10-11 and accompanying full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.
WARNING: ANAPHYLAXIS
See full prescribing information for complete boxed warning. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred after the first dose of XOLAIR but also has occurred beyond 1 year after beginning treatment. Closely observe patients for an appropriate period of time after XOLAIR administration and be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. (5.1)

ADVERSE REACTIONS

Asthma: The most common adverse reactions (≥ 1% of patients) in clinical studies with adult and adolescent patients ≥12 years of age were arthralgia, pain (general), leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. In clinical studies with pediatric patients 6 to <12 years of age, the most common adverse reactions were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis. (6.1)

Chronic idiopathic urticaria: The most common adverse reactions (≥ 3% of patients) in clinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness. (6.1)

Chronic idiopathic urticaria: The most common adverse reactions (≥ 2% of patients) included the following: nausea, nasopharyngitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection, arthralgia, headache, and cough. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

No formal drug interaction studies have been performed. (7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 12/2020

FULL PRESCRIBING INFORMATION: CONTENTS

1 INDICATIONS AND USAGE
1.1 Asthma
1.2 Nasal Polyps
1.3 Chronic Idiopathic Urticaria (CIU)

2 DOSAGE AND ADMINISTRATION
2.1 Overview of Dosage Determination
2.2 Recommended Dosage for Asthma
2.3 Recommended Dosage for Nasal Polyps
2.4 Recommended Dosage for Chronic Idiopathic Urticaria
2.5 Administration
2.6 Preparation for Use and Injection of XOLAIR Prefilled Syringe
2.7 Preparation for Use and Injection of XOLAIR Lyophilized Powder

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS
4.1 Anaphylaxis
4.2 Malignancy
4.3 Acute Asthma Symptoms

5 WARNINGS AND PRECAUTIONS
5.1 Anaphylaxis
5.2 Malignancy
5.3 Corticosteroid Reduction
5.4 Eosinophilic Conditions
5.5 Fever, Arthralgia, and Rash
5.6 Laboratory Tests
5.7 Parasitic (Helminth) Infection
5.8 Pregnancy
5.9 Breastfeeding
5.10 Geriatric Use

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Immunogenicity
6.3 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Pediatric Use
8.4 Geriatric Use

9 DESCRIPTION

10 CLINICAL PHARMACOLOGY
10.1 Mechanism of Action
10.2 Pharmacodynamics
10.3 Pharmacokinetics

11 NONCLINICAL TOXICOLOGY
11.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

12 CLINICAL STUDIES
14.1 Asthma
14.2 Nasal Polyps
14.3 Chronic Idiopathic Urticaria

16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
# FULL PRESCRIBING INFORMATION

## WARNING: ANAPHYLAXIS

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) and Adverse Reactions (6.1, 6.3)].

## 1 INDICATIONS AND USAGE

### 1.1 Asthma

XOLAIR is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.

**Limitations of Use:**
- XOLAIR is not indicated for the relief of acute bronchospasm or status asthmaticus.
- XOLAIR is not indicated for treatment of other allergic conditions.

### 1.2 Nasal Polyps

XOLAIR is indicated for add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

### 1.3 Chronic Idiopathic Urticaria (CIU)

XOLAIR is indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment.

**Limitations of Use:**
XOLAIR is not indicated for treatment of other forms of urticaria.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Overview of Dosage Determination

**Asthma and Nasal Polyps**

Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL) measured before the start of treatment, and by body weight (kg). For patients with both asthma and nasal polyps, dosing determination should be based on the primary diagnosis for which they are treated.
XOLAIR is being prescribed. Adjust doses for significant changes in body weight during treatment (see Tables 1 and 2 for treatment of asthma and Table 3 for treatment of nasal polyps).

Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during XOLAIR treatment cannot be used as a guide for dose determination.

- Interruptions lasting less than one year: Dose based on serum IgE levels obtained at the initial dose determination.
- Interruptions lasting one year or more: Re-test total serum IgE levels for dose determination (Table 1 or 2 for treatment of asthma, based on the patient’s age, and Table 3 for treatment of nasal polyps).

Chronic Idiopathic Urticaria
Dosing XOLAIR in chronic idiopathic urticaria patients is not dependent on serum IgE (free or total) level or body weight.

2.2 Recommended Dosage for Asthma
The recommended dosage for treatment of asthma is XOLAIR 75 mg to 375 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and by body weight (kg) [see Dosage and Administration 2.2].

- Adult and adolescent patients 12 years of age and older: Initiate dosing according to Table 1.
- Pediatric patients 6 to <12 years of age: Initiate dosing according to Table 2.

Table 1. Subcutaneous XOLAIR Doses Every 2 or 4 Weeks* for Patients 12 Years of Age and Older with Asthma

<table>
<thead>
<tr>
<th>Pretreatment Serum IgE (IU/mL)</th>
<th>Dosing Freq.</th>
<th>Body Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>30−60 kg</td>
</tr>
<tr>
<td>≥30−100</td>
<td>Every 4 weeks</td>
<td>150</td>
</tr>
<tr>
<td>&gt;100−200</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>&gt;200−300</td>
<td>300</td>
<td>225</td>
</tr>
<tr>
<td>&gt;300−400</td>
<td>Every 2 weeks</td>
<td>225</td>
</tr>
<tr>
<td>&gt;400−500</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>&gt;500−600</td>
<td>300</td>
<td>375</td>
</tr>
<tr>
<td>&gt;600−700</td>
<td>375</td>
<td></td>
</tr>
</tbody>
</table>

*Dosing frequency:
- Subcutaneous doses to be administered every 4 weeks
- Subcutaneous doses to be administered every 2 weeks
Table 2. Subcutaneous XOLAIR Doses Every 2 or 4 Weeks* for Pediatric Patients with Asthma Who Begin XOLAIR Between the Ages of 6 to <12 Years

<table>
<thead>
<tr>
<th>Pre-treatment Serum IgE (IU/mL)</th>
<th>Dosing Freq.</th>
<th>Body Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>20-25 kg</td>
</tr>
<tr>
<td>30-100</td>
<td>Every 4 weeks</td>
<td>75</td>
</tr>
<tr>
<td>&gt;100-200</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>&gt;200-300</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>&gt;300-400</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;400-500</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;500-600</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;600-700</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;700-800</td>
<td>Every 2 weeks</td>
<td>225</td>
</tr>
<tr>
<td>&gt;800-900</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;900-1000</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;1000-1100</td>
<td></td>
<td>225</td>
</tr>
<tr>
<td>&gt;1100-1200</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>&gt;1200-1300</td>
<td></td>
<td>300</td>
</tr>
</tbody>
</table>

*Dosing frequency:
- Subcutaneous doses to be administered every 4 weeks
- Subcutaneous doses to be administered every 2 weeks

Duration of Therapy
Periodically reassess the need for continued therapy based upon the patient’s disease severity and level of asthma control.

2.3 Recommended Dosage for Nasal Polyps
Administer XOLAIR 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level (IU/mL) measure before the start of treatment and by body weight (kg) [see Dosage and Administration 2.2].
Table 3. Subcutaneous XOLAIR Doses Every 2 or 4 Weeks* for Adult Patients with Nasal Polyps

<table>
<thead>
<tr>
<th>Pretreatment Serum IgE (IU/mL)</th>
<th>Dosing Freq.</th>
<th>Bodyweight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt;30-40 kg</td>
</tr>
<tr>
<td>30 - 100</td>
<td>Every 4 Weeks</td>
<td>75</td>
</tr>
<tr>
<td>&gt;100 - 200</td>
<td>Every 4 Weeks</td>
<td>150</td>
</tr>
<tr>
<td>&gt;200 - 300</td>
<td>Every 4 Weeks</td>
<td>225</td>
</tr>
<tr>
<td>&gt;300 - 400</td>
<td>Every 4 Weeks</td>
<td>300</td>
</tr>
<tr>
<td>&gt;400 - 500</td>
<td>Every 4 Weeks</td>
<td>450</td>
</tr>
<tr>
<td>&gt;500 - 600</td>
<td>Every 4 Weeks</td>
<td>450</td>
</tr>
<tr>
<td>&gt;600 - 700</td>
<td>Every 4 Weeks</td>
<td>450</td>
</tr>
<tr>
<td>&gt;700 - 800</td>
<td>Every 2 Weeks</td>
<td>300</td>
</tr>
<tr>
<td>&gt;800 - 900</td>
<td>Every 2 Weeks</td>
<td>300</td>
</tr>
<tr>
<td>&gt;900 - 1000</td>
<td>Every 2 Weeks</td>
<td>375</td>
</tr>
<tr>
<td>&gt;1000 - 1100</td>
<td>Every 2 Weeks</td>
<td>375</td>
</tr>
<tr>
<td>&gt;1100 - 1200</td>
<td>Every 2 Weeks</td>
<td>450</td>
</tr>
<tr>
<td>&gt;1200 - 1300</td>
<td>Every 2 Weeks</td>
<td>450</td>
</tr>
<tr>
<td>&gt;1300 - 1500</td>
<td>Every 2 Weeks</td>
<td>525</td>
</tr>
</tbody>
</table>

*Dosing frequency:

- Subcutaneous doses to be administered every 4 weeks
- Subcutaneous doses to be administered every 2 weeks

Duration of Therapy

Periodically reassess the need for continued therapy based upon the patient’s disease severity and level of symptom control.

2.4 Recommended Dosage for Chronic Idiopathic Urticaria

Administer XOLAIR 150 mg or 300 mg by subcutaneous injection every 4 weeks. Dosing of XOLAIR in CIU patients is not dependent on serum IgE (free or total) level or body weight.

Duration of Therapy

The appropriate duration of therapy for CIU has not been evaluated. Periodically reassess the need for continued therapy.
2.5 Administration
XOLAIR is available as a prefilled syringe and as a lyophilized powder in vial for reconstitution. Both XOLAIR prefilled syringe and lyophilized powder should be administered by a healthcare professional. Administer XOLAIR by subcutaneous injection. The injection may take 5-10 seconds to administer. Do not administer more than one injection per site. (Table 4, Table 5).

Table 4. Number of Prefilled Syringes, Injections and Total Injection Volumes

<table>
<thead>
<tr>
<th>XOLAIR Dose*</th>
<th>75 mg Syringes</th>
<th>150 mg Syringes</th>
<th>Total Volume Injected</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 mg</td>
<td>1</td>
<td>0</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>150 mg</td>
<td>0</td>
<td>1</td>
<td>1 mL</td>
</tr>
<tr>
<td>225 mg</td>
<td>1</td>
<td>1</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>300 mg</td>
<td>0</td>
<td>2</td>
<td>2 mL</td>
</tr>
<tr>
<td>375 mg</td>
<td>1</td>
<td>2</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>450 mg</td>
<td>0</td>
<td>3</td>
<td>3 mL</td>
</tr>
<tr>
<td>525 mg</td>
<td>1</td>
<td>3</td>
<td>3.5 mL</td>
</tr>
<tr>
<td>600 mg</td>
<td>0</td>
<td>4</td>
<td>4 mL</td>
</tr>
</tbody>
</table>

* The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients. All doses in the table are approved for use in nasal polyps patients. The 150 mg and 300 mg XOLAIR doses are also approved for use in CIU patients.

Table 5. Number of Vials, Injections and Total Injection Volumes

<table>
<thead>
<tr>
<th>XOLAIR Dose*</th>
<th>Number of Vials</th>
<th>Number of Injections</th>
<th>Total Volume Injected</th>
</tr>
</thead>
<tbody>
<tr>
<td>75 mg</td>
<td>1</td>
<td>1</td>
<td>0.6 mL</td>
</tr>
<tr>
<td>150 mg</td>
<td>1</td>
<td>1</td>
<td>1.2 mL</td>
</tr>
<tr>
<td>225 mg</td>
<td>2</td>
<td>2</td>
<td>1.8 mL</td>
</tr>
<tr>
<td>300 mg</td>
<td>2</td>
<td>2</td>
<td>2.4 mL</td>
</tr>
<tr>
<td>375 mg</td>
<td>3</td>
<td>3</td>
<td>3.0 mL</td>
</tr>
<tr>
<td>450 mg</td>
<td>3</td>
<td>3</td>
<td>3.6 mL</td>
</tr>
<tr>
<td>525 mg</td>
<td>4</td>
<td>4</td>
<td>4.2 mL</td>
</tr>
<tr>
<td>600 mg</td>
<td>4</td>
<td>4</td>
<td>4.8 mL</td>
</tr>
</tbody>
</table>

* The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients. All doses in the table are approved for use in nasal polyps patients. The 150 mg and 300 mg XOLAIR doses are also approved for use in CIU patients.

2.6 Preparation for Use and Injection of XOLAIR Prefilled Syringe
To prepare XOLAIR prefilled syringes for subcutaneous administration, please carefully read and adhere to these instructions for use.
XOLAIR prefilled syringes are available in 2 dose strengths. These instructions are to be used for both dose strengths. You should check the label on the carton that comes with the XOLAIR prefilled syringe to make sure that the dose is correct.

- **XOLAIR 75 mg** prefilled syringe with a blue needle shield

- **XOLAIR 150 mg** prefilled syringe with a purple needle shield

**Storage Instructions**
- Keep the unused syringe in the original carton and store the carton in a refrigerator at 36°F to 46°F (2°C to 8°C). **Do not** remove the syringe from its original carton during storage.
- Keep the XOLAIR syringe out of direct sunlight.
- **Do not** freeze.
- **Do not** use if the syringe has been frozen.
- Always keep the syringe dry.
Important Information about the Prefilled Syringe

- The removable needle cap of XOLAIR solution for injection in prefilled syringe contains a derivative of natural rubber latex [see Description (11)].
- **Do not** open the sealed outer carton until you are ready to inject XOLAIR.
- **Do not** take the needle cap off until you are ready to inject XOLAIR.
- **Do not** try to take the syringe apart at any time.
- **Do not** reuse the same syringe.
- **Do not** use if the syringe has been dropped or damaged.
- **Do not** use if the packaging is damaged or appears to be tampered with.
- **Do not** leave the syringe unattended.
- Keep the syringe out of the reach of children.

Preparing for the Injection

1. Find a clean, flat, working surface.
   - Each XOLAIR carton contains 1 syringe.
   - Take the carton containing the syringe out of the refrigerator.
2. Check the expiration date on the XOLAIR carton.
   - **Do not** use it if the expiration date has passed because it may not be safe to use. If the expiration date has passed, safely dispose of the syringe in a sharps container (see step 14 at the end of these instructions for use).
3. Place the carton on a clean flat, surface.
   - Set aside the carton for at least 15-30 minutes so the syringe can warm up on its own to room temperature (leave the syringe in the carton to protect it from light).
   - If the syringe does not reach room temperature, this could cause the injection to feel uncomfortable and make it hard to push the plunger.
   - **Do not** allow the syringe to become hot.
   - **Do not** speed up the warming process in any way, and do not put the syringe in a microwave or in warm water.
4. Open the carton.
   - Wash your hands with soap and water.
   - Take the blister pack out of the carton.
   - Check the expiration date on blister pack.
   - **Do not** use it if the expiration date has passed because it may not be safe to use. If the expiration date has passed, safely dispose of the syringe in a sharps container (see step 14 at the end of these instructions for use).
• Be careful when taking out the syringe. **Do not** flip the blister pack upside down to take out the syringe, and **do not** touch the back of the syringe. This may damage the syringe.
• Peel off the blister pack cover. Take the syringe out of the blister pack by holding the middle part of the syringe. When holding the syringe, make sure you always hold the syringe as shown.
• **Do not** handle the syringe by holding the plunger or needle cap.

5 Inspect the syringe closely.
• Check the syringe. The liquid in the syringe should be clear to slightly opalescent and colorless to pale brownish-yellow. **Do not** use the syringe if the liquid is cloudy, discolored, or contains foreign particles.
• Check the expiration date on the syringe. **Do not** use the syringe if the expiration date has passed because it may not be safe to use.
• If the medicine does not look as described or if the expiration date has passed, safely dispose of the syringe in a sharps container (see step 14 at the end of these instructions for use).

6 Choose an injection site.
• The recommended injection sites are the upper arm and the front and middle of the thighs.
• **Do not** inject into moles, scars, bruises, or areas where the skin is tender, red, hard, or if there are breaks in the skin.
• Choose a different injection site for each new injection at least 1 inch from the area used for the last injection.

7 Wipe the injection site with an alcohol pad in a circular motion and let it air dry for 10 seconds.
• **Do not** touch the injection site again before giving the injection.
• **Do not** fan or blow on the cleaned area.
**Administering the Injection**

8 Hold the syringe firmly with 1 hand and pull the needle cap straight off with your other hand.
   • **Do not** hold the plunger while you remove the needle cap.
   • **Do not** touch the needle after removing the needle cap.
   • Throw away the needle cap in a sharps container right away.
   • There may be a small air bubble in the syringe. This is normal and you should not try to remove the air bubble.
   • You may also see a drop of liquid at the end of the needle. This is also normal and will not affect the dose.

9 Use your other hand and gently pinch the area of skin that was cleaned. Hold the pinched skin tight.
   • Pinching the skin is important to make sure that you inject under the skin (into the fatty area) but not any deeper (into muscle).

10 Continue holding the syringe by the center and use a quick, dart-like motion to insert the needle all the way into the pinched skin at an angle between 45° to 90°. It is important to use the correct angle to make sure the medicine is delivered under the skin (into the fatty area), or the injection could be uncomfortable and the medicine may not work.
   • **Do not** touch the plunger while inserting the needle into the skin.
   • **Do not** insert the needle through clothing. Once the needle is inserted, hold the syringe tightly in place and **do not** change the angle of injection or insert the needle again. The patient should not move and should avoid sudden movements throughout the injection.

11 Slowly inject all of the medicine by gently pushing the plunger all the way down.
   • You must press the plunger all the way down to make sure that the full dose of medicine gets injected. If the plunger is not fully pressed, the needle shield will not extend to cover the needle when it is removed.
12 Gently release the plunger and allow the needle to be covered by the needle-shield.
   • If the needle is not covered, proceed carefully to dispose of the syringe (see step 14 at the end of these instructions for use).

After the Injection
13 There may be a little bleeding at the injection site. You can press a cotton ball or gauze over the injection site.
   • Do not rub the injection site.
   • If needed, you may cover the injection site with a small bandage.
   • In case of skin contact with medicine, wash the area that touched the medicine with water.
14 The XOLAIR prefilled syringe is a single-dose syringe and should not be used again.
   • Put the used XOLAIR prefilled syringe in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the prefilled syringe in the trash.
   • Do not put the needle cap back on the needle.

2.7 Preparation for Use and Injection of XOLAIR Lyophilized Powder
The supplied XOLAIR lyophilized powder must be reconstituted with Sterile Water for Injection (SWFI) USP, using the following instructions:
1) Before reconstitution, determine the number of vials that will need to be reconstituted (each vial delivers 150 mg of XOLAIR in 1.2 mL) (see Table 5).
2) Draw 1.4 mL of SWFI, USP, into a 3 mL syringe equipped with a 1-inch, 18-gauge needle.
3) Place the vial upright on a flat surface and using standard aseptic technique, insert the needle and inject the SWFI, USP, directly onto the product.
4) Keeping the vial upright, gently swirl the upright vial for approximately 1 minute to evenly wet the powder. Do not shake.
5) Gently swirl the vial for 5 to 10 seconds approximately every 5 minutes in order to dissolve any remaining solids. The lyophilized product takes 15 to 20 minutes to dissolve. If it takes longer than 20 minutes to dissolve completely, gently swirl the vial for 5 to 10 seconds approximately every 5 minutes until there are no visible gel-like particles in the solution. Do not use if the contents of the vial do not dissolve completely by 40 minutes.
6) After reconstitution, XOLAIR solution is somewhat viscous and will appear clear or slightly opalescent. It is acceptable if there are a few small bubbles or foam around the edge of the vial; there should be no visible gel-like particles in the reconstituted solution. Do not use if foreign particles are present.
7) Invert the vial for 15 seconds in order to allow the solution to drain toward the stopper.

8) **Use the XOLAIR solution within 8 hours following reconstitution when stored in the vial at 2ºC to 8ºC (36ºF to 46ºF), or within 4 hours of reconstitution when stored at room temperature.** Reconstituted XOLAIR vials should be protected from sunlight.

9) Using a new 3 mL syringe equipped with a 1-inch, 18-gauge needle, insert the needle into the inverted vial. Position the needle tip at the very bottom of the solution in the vial stopper when drawing the solution into the syringe. The reconstituted product is somewhat viscous. **Withdraw all of the product** from the vial before expelling any air or excess solution from the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove all of the solution from the inverted vial.

10) Replace the 18-gauge needle with a 25-gauge needle for subcutaneous injection.

11) Expel air, large bubbles, and any excess solution in order to obtain a volume of 1.2 mL corresponding to a dose of 150 mg of XOLAIR. To obtain a volume of 0.6 mL corresponding to a dose of 75 mg of XOLAIR, expel air, large bubbles and discard 0.6 mL from the syringe. A thin layer of small bubbles may remain at the top of the solution in the syringe.

12) Administer XOLAIR by subcutaneous injection. The injection may take 5-10 seconds to administer because the solution is slightly viscous. Do not administer more than 150 mg (contents of one vial) per injection site. Divide doses of more than 150 mg among two or more injection sites.

3 **DOSAGE FORMS AND STRENGTHS**
- Injection: 75 mg/0.5 mL is a clear to slightly opalescent and colorless to pale brownish-yellow solution in a single-dose prefilled syringe with blue needle shield
- Injection: 150 mg/mL is a clear to slightly opalescent and colorless to pale brownish-yellow solution in a single-dose prefilled syringe with purple needle shield
- For injection: 150 mg white lyophilized powder in a single-dose vial for reconstitution

4 **CONTRAINDICATIONS**
XOLAIR is contraindicated in patients with severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR [see Warnings and Precautions (5.1)].

5 **WARNINGS AND PRECAUTIONS**

5.1 **Anaphylaxis**
Anaphylaxis has been reported to occur after administration of XOLAIR in premarketing clinical trials and in postmarketing spontaneous reports [see Boxed Warning and Adverse Reactions (6.3)]. Signs and symptoms in these reported cases have included bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue. Some of these events have been life-threatening. In premarketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3507 (0.1%) patients. Anaphylaxis occurred with the first dose of XOLAIR in two patients and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient.
A case-control study showed that, among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis [see Adverse Reactions (6.1)].

In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond one year after beginning regularly scheduled treatment.

Administer XOLAIR only in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. Observe patients closely for an appropriate period of time after administration of XOLAIR, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports [see Adverse Reactions (6)]. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs or symptoms occur.

Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction [see Contraindications (4)].

5.2 Malignancy
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of adults and adolescents ≥12 years of age with asthma and other allergic disorders. The observed malignancies in XOLAIR-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The majority of patients were observed for less than 1 year. The impact of longer exposure to XOLAIR or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known.

In a subsequent observational study of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated adolescent and adult patients with moderate to severe persistent asthma and a positive skin test reaction or in vitro reactivity to a perennial aeroallergen, patients were followed for up to 5 years. In this study, the incidence rates of primary malignancies (per 1000 patient years) were similar among XOLAIR-treated (12.3) and non-XOLAIR-treated patients (13.0) [see Adverse Reactions (6)]. However, study limitations preclude definitively ruling out a malignancy risk with XOLAIR. Study limitations include: the observational study design, the bias introduced by allowing enrollment of patients previously exposed to XOLAIR (88%), enrollment of patients (56%) while a history of cancer or a premalignant condition were study exclusion criteria, and the high study discontinuation rate (44%).

5.3 Acute Asthma Symptoms
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus.

5.4 Corticosteroid Reduction
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of XOLAIR therapy for asthma or nasal polyps. Decrease corticosteroids gradually under the direct
supervision of a physician. In CIU patients, the use of XOLAIR in combination with corticosteroids has not been evaluated.

5.5 Eosinophilic Conditions
In rare cases, patients with asthma on therapy with XOLAIR may present with serious systemic eosinophilia sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between XOLAIR and these underlying conditions has not been established.

5.6 Fever, Arthralgia, and Rash
In post-approval use, some patients have experienced a constellation of signs and symptoms including arthritis/arthralgia, rash, fever and lymphadenopathy with an onset 1 to 5 days after the first or subsequent injections of XOLAIR. These signs and symptoms have recurred after additional doses in some patients. Although circulating immune complexes or a skin biopsy consistent with a Type III reaction were not seen with these cases, these signs and symptoms are similar to those seen in patients with serum sickness. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms [see Adverse Reactions (6.3)].

5.7 Parasitic (Helminth) Infection
Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.

In a one-year clinical trial conducted in Brazil in adult and adolescent patients at high risk for geohelminthic infections (roundworm, hookworm, whipworm, threadworm), 53% (36/68) of XOLAIR-treated patients experienced an infection, as diagnosed by standard stool examination, compared to 42% (29/69) of placebo controls. The point estimate of the odds ratio for infection was 1.96, with a 95% confidence interval (0.88, 4.36) indicating that in this study a patient who had an infection was anywhere from 0.88 to 4.36 times as likely to have received XOLAIR than a patient who did not have an infection. Response to appropriate anti-geohelminth treatment of infection as measured by stool egg counts was not different between treatment groups.

5.8 Laboratory Tests
Serum total IgE levels increase following administration of XOLAIR due to formation of XOLAIR:IgE complexes [see Clinical Pharmacology (12.2)]. Elevated serum total IgE levels may persist for up to 1 year following discontinuation of XOLAIR. Do not use serum total IgE levels obtained less than 1 year following discontinuation to reassess the dosing regimen for asthma or nasal polyps patients, because these levels may not reflect steady state free IgE levels [see Dosage and Administration (2.2, 2.3)].

6 ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:

- Anaphylaxis [see Boxed Warning and Warnings and Precautions (5.1)]
- Malignancies [see Warnings and Precautions (5.2)]
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions from Clinical Studies in Adult and Adolescent Patients 12 Years of Age and Older with Asthma

The data described below reflect XOLAIR exposure for 2076 adult and adolescent patients ages 12 and older, including 1687 patients exposed for six months and 555 exposed for one year or more, in either placebo-controlled or other controlled asthma studies. The mean age of patients receiving XOLAIR was 42 years, with 134 patients 65 years of age or older; 60% were women, and 85% Caucasian. Patients received XOLAIR 150 mg to 375 mg every 2 or 4 weeks or, for patients assigned to control groups, standard therapy with or without a placebo.

The adverse events most frequently resulting in clinical intervention (e.g., discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event) were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Table 6 shows adverse reactions from four placebo-controlled asthma trials that occurred ≥1% and more frequently in adult and adolescent patients 12 years of age and older receiving XOLAIR than in those receiving placebo. Adverse events were classified using preferred terms from the International Medical Nomenclature (IMN) dictionary. Injection site reactions were recorded separately from the reporting of other adverse events.
Table 6. Adverse Reactions ≥1% More Frequent in XOLAIR-Treated Adult or Adolescent Patients 12 years of Age and Older in Four Placebo-controlled Asthma Trials

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>XOLAIR n=738</th>
<th>Placebo n=717</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body as a whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Musculoskeletal system</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>8%</td>
<td>6%</td>
</tr>
<tr>
<td>Fracture</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Leg pain</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>Arm pain</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Nervous system</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Skin and appendages</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Dermatitis</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Special senses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earache</td>
<td>2%</td>
<td>1%</td>
</tr>
</tbody>
</table>

There were no differences in the incidence of adverse reactions based on age (among patients under 65), gender or race.

**Anaphylaxis Case Control Study**

A retrospective case-control study investigated risk factors for anaphylaxis to XOLAIR among patients treated with XOLAIR for asthma. Cases with an adjudicated history of anaphylaxis to XOLAIR were compared to controls with no such history. The study found that a self-reported history of anaphylaxis to foods, medications or other causes was more common among patients with XOLAIR anaphylaxis (57% of 30 cases) compared to controls (23% of 88 controls) [OR 8.1, 95% CI 2.7 to 24.3]. Because this is a case-control study, the study cannot provide the incidence of anaphylaxis among XOLAIR users. From other sources, anaphylaxis to XOLAIR was observed in 0.1% of patients in clinical trials and at least 0.2% of patients based upon postmarketing reports [see Warnings and Precautions (5.1), Adverse Reactions (6.3)].

**Injection Site Reactions**

In adults and adolescents, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. The types of injection site reactions included: bruising, redness, warmth, burning, stinging, itching, hives formation, pain, indurations, mass, and inflammation.

Severe injection site reactions occurred more frequently in XOLAIR-treated patients compared with patients in the placebo group (12% versus 9%).
The majority of injection site reactions occurred within 1 hour post injection, lasted less than 8 days, and generally decreased in frequency at subsequent dosing visits.

Adverse Reactions from Clinical Studies in Pediatric Patients 6 to <12 Years of Age with Asthma
The data described below reflect XOLAIR exposure for 926 patients 6 to <12 years of age, including 583 patients exposed for six months and 292 exposed for one year or more, in either placebo-controlled or other controlled asthma studies. The mean age of pediatric patients receiving XOLAIR was 8.8 years; 69% were male, and 64% were Caucasian. Pediatric patients received XOLAIR 75 mg to 375 mg every 2 or 4 weeks or, for patients assigned to control groups, standard therapy with or without a placebo. No cases of malignancy were reported in patients treated with XOLAIR in these trials.

The most common adverse reactions occurring at ≥3% in the pediatric patients receiving XOLAIR and more frequently than in patients treated with placebo were nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, and epistaxis.

The adverse events most frequently resulting in clinical intervention (e.g., discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event) were bronchitis (0.2%), headache (0.2%) and urticaria (0.2%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Adverse Reactions from Clinical Studies in Adult Patients with Nasal Polyps
The data described below reflect XOLAIR exposure for 135 patients ≥18 years of age, exposed for six months in two placebo-controlled studies. The mean age of patients receiving XOLAIR was 49.7 years; 64% were male, and 94% were Caucasian. Patients received XOLAIR or placebo SC every 2 or 4 weeks, with dosage and frequency according to Table 3. All patients received background nasal mometasone therapy throughout the study. Table 7 lists the adverse reactions occurring in ≥3% of XOLAIR-treated patients and more frequently than in patients treated with placebo in Nasal Polyps Trials 1 and 2; results were pooled.
Table 7. Adverse Reactions Occurring in ≥3% of XOLAIR-Treated Patients and More Frequently than in Patients Treated with Placebo in Nasal Polyps Trials 1 and 2

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>XOLAIR n=135</th>
<th>Placebo n=130</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>4 (3.0%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reactions*</td>
<td>7 (5.2%)</td>
<td>2 (1.5%)</td>
</tr>
<tr>
<td>Musculoskeletal system and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>4 (3.0%)</td>
<td>2 (1.5%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>11 (8.1%)</td>
<td>7 (5.4%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4 (3.0%)</td>
<td>1 (0.8%)</td>
</tr>
</tbody>
</table>

*Injection site reactions terms: ‘injection site reaction’, ‘injection related reaction’ and ‘injection site pain’. All of the injection site reactions were mild to moderate severity and none resulted in study discontinuation.

Adverse Reactions from Clinical Studies in Patients with Chronic Idiopathic Urticaria (CIU)
The safety of XOLAIR for the treatment of CIU was assessed in three placebo-controlled, multiple-dose clinical trials of 12 weeks’ (CIU Trial 2) and 24 weeks’ duration (CIU Trials 1 and 3). In CIU Trials 1 and 2, patients received XOLAIR 75 mg, 150 mg, or 300 mg or placebo every 4 weeks in addition to their baseline level of H1 antihistamine therapy throughout the treatment period. In CIU Trial 3 patients were randomized to XOLAIR 300 mg or placebo every 4 weeks in addition to their baseline level of H1 antihistamine therapy. The data described below reflect XOLAIR exposure for 733 patients enrolled and receiving at least one dose of XOLAIR in the three clinical trials, including 684 patients exposed for 12 weeks and 427 exposed for 24 weeks. The mean age of patients receiving XOLAIR 300 mg was 43 years, 75% were women, and 89% were white. The demographic profiles for patients receiving XOLAIR 150 mg and 75 mg were similar.

Table 8 shows adverse reactions that occurred in ≥2% of patients receiving XOLAIR (150 or 300 mg) and more frequently than those receiving placebo. Adverse reactions are pooled from Trial 2 and the first 12 weeks of Trials 1 and 3.
Table 8. Adverse Reactions Occurring in ≥2% in XOLAIR-Treated Patients and More Frequently than in Patients Treated with Placebo (Day 1 to Week 12) in CIU Trials

<table>
<thead>
<tr>
<th>Adverse Reactions*</th>
<th>CIU Trials 1, 2 and 3 Pooled</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>150mg (n=175)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (1.1%)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>16 (9.1%)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2 (1.1%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>2 (1.1%)</td>
</tr>
<tr>
<td>Viral upper respiratory tract infection</td>
<td>4 (2.3%)</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (2.9%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>21 (12.0%)</td>
</tr>
<tr>
<td>Respiratory, thoracic, and mediastinal disorders</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>2 (1.1%)</td>
</tr>
</tbody>
</table>

* by MedDRA (15.1) System Organ Class and Preferred Term

Additional reactions reported during the 24-week treatment period in Trials 1 and 3 [≥2% of patients receiving XOLAIR (150 mg or 300 mg) and more frequently than those receiving placebo] included: toothache, fungal infection, urinary tract infection, myalgia, pain in extremity, musculoskeletal pain, peripheral edema, pyrexia, migraine, sinus headache, anxiety, oropharyngeal pain, asthma, urticaria, and alopecia.

**Injection Site Reactions**

Injection site reactions of any severity occurred during the studies in more XOLAIR-treated patients [11 patients (2.7%) at 300 mg, 1 patient (0.6%) at 150 mg] compared with 2 placebo-treated patients (0.8%). The types of injection site reactions included: swelling, erythema, pain, bruising, itching, bleeding and urticaria. None of the events resulted in study discontinuation or treatment interruption.

**Cardiovascular and Cerebrovascular Events from Clinical Studies in Patients with Asthma**

A 5-year observational cohort study was conducted in patients ≥12 years of age with moderate to severe persistent asthma and a positive skin test reaction to a perennial aeroallergen to evaluate the long term safety of XOLAIR, including the risk of malignancy [see Warnings and Precautions (5.2)]. A total of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated patients enrolled in the study. Similar percentages of patients in both cohorts were current (5%) or former smokers (29%). Patients had a mean age of 45 years and were followed for a mean of 3.7 years. More XOLAIR-treated patients were diagnosed with severe asthma (50%) compared to the non-XOLAIR-treated patients (23%) and 44% of
patients prematurely discontinued the study. Additionally, 88% of patients in the XOLAIR-treated cohort had been previously exposed to XOLAIR for a mean of 8 months.

A higher incidence rate (per 1000 patient-years) of overall cardiovascular and cerebrovascular serious adverse events (SAEs) was observed in XOLAIR-treated patients (13.4) compared to non-XOLAIR-treated patients (8.1). Increases in rates were observed for transient ischemic attack (0.7 versus 0.1), myocardial infarction (2.1 versus 0.8), pulmonary hypertension (0.5 versus 0), pulmonary embolism/venous thrombosis (3.2 versus 1.5), and unstable angina (2.2 versus 1.4), while the rates observed for ischemic stroke and cardiovascular death were similar among both study cohorts. The results suggest a potential increased risk of serious cardiovascular and cerebrovascular events in patients treated with XOLAIR. However, the observational study design, the inclusion of patients previously exposed to XOLAIR (88%), baseline imbalances in cardiovascular risk factors between the treatment groups, an inability to adjust for unmeasured risk factors, and the high study discontinuation rate limit the ability to quantify the magnitude of the risk.

A pooled analysis of 25 randomized double-blind, placebo-controlled clinical trials of 8 to 52 weeks in duration was conducted to further evaluate the imbalance in cardiovascular and cerebrovascular SAEs noted in the above observational cohort study. A total of 3342 XOLAIR-treated patients and 2895 placebo-treated patients were included in the pooled analysis. The patients had a mean age of 38 years, and were followed for a mean duration of 6.8 months. No notable imbalances were observed in the rates of cardiovascular and cerebrovascular SAEs listed above. However, the results of the pooled analysis were based on a low number of events, slightly younger patients, and shorter duration of follow-up than the observational cohort study; therefore, the results are insufficient to confirm or reject the findings noted in the observational cohort study.

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to omalizumab in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Antibodies to XOLAIR were detected in approximately 1/1723 (<0.1%) of patients treated with XOLAIR in the clinical studies evaluated for asthma in patients 12 years of age and older. In three pediatric studies, antibodies to XOLAIR were detected in one patient out of 581 patients 6 to <12 years of age treated with XOLAIR and evaluated for antibodies. There were no detectable antibodies in the patients treated in the CIU clinical trials, but due to levels of XOLAIR at the time of anti-therapeutic antibody sampling and missing samples for some patients, antibodies to XOLAIR could only have been determined in 88% of the 733 patients treated in these clinical studies. The data reflect the percentage of patients whose test results were considered positive for antibodies to XOLAIR in ELISA assays and are highly dependent on the sensitivity and specificity of the assays.
6.3 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of XOLAIR in adult and adolescent patients 12 years of age and older. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Anaphylaxis: Based on spontaneous reports and an estimated exposure of about 57,300 patients from June 2003 through December 2006, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients. Diagnostic criteria of anaphylaxis were skin or mucosal tissue involvement, and, either airway compromise, and/or reduced blood pressure with or without associated symptoms, and a temporal relationship to XOLAIR administration with no other identifiable cause. Signs and symptoms in these reported cases included bronchospasm, hypotension, syncope, urticaria, angioedema of the throat or tongue, dyspnea, cough, chest tightness, and/or cutaneous angioedema. Pulmonary involvement was reported in 89% of the cases. Hypotension or syncope was reported in 14% of cases. Fifteen percent of the reported cases resulted in hospitalization. A previous history of anaphylaxis unrelated to XOLAIR was reported in 24% of the cases.

Of the reported cases of anaphylaxis attributed to XOLAIR, 39% occurred with the first dose, 19% occurred with the second dose, 10% occurred with the third dose, and the rest after subsequent doses. One case occurred after 39 doses (after 19 months of continuous therapy, anaphylaxis occurred when treatment was restarted following a 3-month gap). The time to onset of anaphylaxis in these cases was up to 30 minutes in 35%, greater than 30 and up to 60 minutes in 16%, greater than 60 and up to 90 minutes in 2%, greater than 90 and up to 120 minutes in 6%, greater than 2 hours and up to 6 hours in 5%, greater than 6 hours and up to 12 hours in 14%, greater than 12 hours and up to 24 hours in 8%, and greater than 24 hours and up to 4 days in 5%. In 9% of cases the times to onset were unknown.

Twenty-three patients who experienced anaphylaxis were rechallenged with XOLAIR and 18 patients had a recurrence of similar symptoms of anaphylaxis. In addition, anaphylaxis occurred upon rechallenge with XOLAIR in 4 patients who previously experienced urticaria only.

Eosinophilic Conditions: Eosinophilic conditions have been reported [see Warnings and Precautions (5.5)].

Fever, Arthralgia, and Rash: A constellation of signs and symptoms including arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy similar to serum sickness have been reported in post-approval use of XOLAIR [see Warnings and Precautions (5.6)].

Hematologic: Severe thrombocytopenia has been reported.

Skin: Hair loss has been reported.

7 DRUG INTERACTIONS

No formal drug interaction studies have been performed with XOLAIR.

In patients with asthma and nasal polyps, the concomitant use of XOLAIR and allergen immunotherapy has not been evaluated.
In patients with CIU, the use of XOLAIR in combination with immunosuppressive therapies has not been studied.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
A registry study of XOLAIR exposure during pregnancy showed no increase in the rate of major birth defects or miscarriage. There was an increased rate of low birth weight among registry infants compared to infants in the other cohorts, despite average gestational age at birth; however, women taking XOLAIR during pregnancy also had more severe asthma, which makes it difficult to determine whether the low birth weight is due to the drug or the disease severity [see Data]. There are risks associated with poorly or moderately controlled asthma in pregnancy [see Clinical Considerations].

Human IgG antibodies are known to cross the placental barrier; therefore, XOLAIR may be transmitted from the mother to the developing fetus.

In animal reproduction studies, no evidence of fetal harm was observed in Cynomolgus monkeys with subcutaneous doses of omalizumab up to approximately 5 times the maximum recommended human dose (MRHD) [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk
In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

Data

Human Data
A prospective cohort pregnancy exposure registry study conducted in the US from 2006 to 2018, included 250 pregnant women with asthma treated with XOLAIR. Of these, 246 patients were exposed to XOLAIR in the first trimester of pregnancy, and the median exposure duration was 8.7 months.

The registry findings for applicable mother and infant subgroups were compared to age-adjusted frequencies in a disease matched external cohort of 1,153 pregnant women with asthma (without exposure to XOLAIR) identified from healthcare databases of residents in the Canadian province of Quebec, and referred to as the Quebec External Comparator Cohort (“comparator cohort”).
Among applicable registry infants, the prevalence of major congenital anomalies (8.1%) was similar to that for infants in the comparator cohort (8.9%). Among applicable registry
pregnancies, 99.1% led to live births, similar to 99.3% for the comparator cohort. There was an increased rate of low birth weight among registry infants (13.7%) as compared to the comparator cohort (9.8%); however, women taking XOLAIR during pregnancy also had more severe asthma, which makes it difficult to determine whether the low birth weight is due to the drug or the disease severity.

The registry study cannot definitively establish the absence of any risk because of methodological limitations, including the observational nature of the registry, small sample size, and potential differences between the registry population and the comparator cohort.

**Animal Data**

Reproductive studies have been performed in Cynomolgus monkeys. There was no evidence of maternal toxicity, embryotoxicity, or teratogenicity when omalizumab was administered throughout the period of organogenesis at doses that produced exposures approximately 5 times the MHRD (on a mg/kg basis with maternal subcutaneous doses up to 75 mg/kg/week). Omalizumab did not elicit adverse effects on fetal or neonatal growth when administered throughout late gestation, delivery, and nursing.

**8.2 Lactation**

*Risk Summary*

There is no information regarding the presence of omalizumab in human milk, or the effects on milk production. However, omalizumab is a human monoclonal antibody (IgG1 kappa), and immunoglobulin (IgG) is present in human milk in small amounts.

The majority of infants (80.9%, 186/230) in the pregnancy exposure registry were breastfed. Events categorized as “infections and infestations” were not significantly increased in infants who were exposed to XOLAIR through breastfeeding compared with infants who were not breastfed, or infants who were breastfed without exposure to XOLAIR.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for XOLAIR and any potential adverse effects on the breastfed child from omalizumab or from the underlying maternal condition.

**8.4 Pediatric Use**

*Asthma*

Safety and effectiveness of XOLAIR for moderate to severe persistent asthma who had a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids, have been established in pediatric patients aged 6 years and older. Use of XOLAIR for this indication is supported by evidence from adequate and well-controlled studies. XOLAIR was evaluated in 2 trials in 926 (XOLAIR 624; placebo 302) pediatric patients 6 to <12 years of age with moderate to severe persistent asthma who had a positive skin test or in vitro reactivity to a perennial aeroallergen. One trial was a pivotal trial of similar design and conduct to that of adult and adolescent Asthma Trials 1 and 2. The other trial was primarily a safety study and included evaluation of efficacy as a secondary outcome. In the pivotal trial, XOLAIR-treated patients had a statistically significant reduction in the rate of exacerbations (exacerbation was defined as worsening of asthma that required treatment with systemic corticosteroids or a doubling of the baseline ICS dose) [see Clinical Studies (14.1)].
Safety and efficacy in pediatric patients with asthma below 6 years of age have not been established.

**Nasal Polyps**
Safety and effectiveness in pediatric patients with nasal polyps below 18 years of age have not been established.

**Chronic Idiopathic Urticaria**
The safety and effectiveness of XOLAIR for chronic idiopathic urticaria have been established in pediatric patients aged 12 years and older. Use of XOLAIR in this population is supported by evidence from adequate and well-controlled studies. Adolescent patients with CIU were evaluated in 39 patients 12 to 17 years of age (XOLAIR 29, placebo 10) included in three randomized, placebo-controlled CIU trials. A numerical decrease in weekly itch score was observed, and adverse reactions were similar to those reported in patients 18 years and older.

Safety and effectiveness in pediatric patients with CIU below 12 years of age have not been established.

**8.5 Geriatric Use**
In clinical studies, 134 asthma patients, 20 nasal polyps patients, and 37 CIU phase 3 study patients 65 years of age or older were treated with XOLAIR. Although there were no apparent age-related differences observed in these studies, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.

**11 DESCRIPTION**
Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody has a molecular weight of approximately 149 kiloDaltons. XOLAIR is produced by a Chinese hamster ovary cell suspension culture.

XOLAIR (omalizumab) is administered as a subcutaneous (SC) injection and is available in prefilled syringes and in vials.

**XOLAIR Injection (Prefilled Syringe)**
XOLAIR (omalizumab) injection is supplied as a sterile, preservative-free, clear to slightly opalescent and colorless to pale brownish-yellow solution for subcutaneous injection. XOLAIR (omalizumab) injection is available as a single-dose prefilled syringe.

Each 75 mg prefilled syringe delivers 75 mg omalizumab in 0.5 mL and contains L-arginine hydrochloride (21.05 mg), L-histidine (0.68 mg), L-histidine hydrochloride monohydrate (1.17 mg), and polysorbate 20 (0.2 mg) in Sterile Water for Injection (SWFI), USP.

Each 150 mg prefilled syringe delivers 150 mg omalizumab in 1 mL and contains L-arginine hydrochloride (42.1 mg), L-histidine (1.37 mg), L-histidine hydrochloride monohydrate (2.34 mg), and polysorbate 20 (0.4 mg) in SWFI, USP.
The needle cap contains a derivative of natural rubber latex which may cause allergic reactions in latex sensitive individuals.

**XOLAIR for Injection (Vial)**

XOLAIR (omalizumab) for injection is a sterile, white, preservative free, lyophilized powder in a single-dose vial. After reconstitution with 1.4 mL of Sterile Water for Injection, USP, the vial contains 150 mg of omalizumab per 1.2 mL of reconstituted solution for subcutaneous injection. Each 1.2 mL of reconstituted solution also contains L-histidine (1.3 mg), L-histidine hydrochloride monohydrate (2.1 mg), polysorbate 20 (0.4 mg) and sucrose (108 mg).

### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

**Asthma and Nasal Polyps**

Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation on these cells. In allergic asthmatics, treatment with omalizumab inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL-4, IL-5, and IL-13.

**Chronic Idiopathic Urticaria**

Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FceRI) on cells down-regulate. The mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown.

#### 12.2 Pharmacodynamics

**Asthma**

In clinical studies, serum free IgE levels were reduced in a dose dependent manner within 1 hour following the first dose and maintained between doses. Mean serum free IgE decrease was greater than 96% using recommended doses. Serum total IgE levels (i.e., bound and unbound) increased after the first dose due to the formation of omalizumab:IgE complexes, which have a slower elimination rate compared with free IgE. At 16 weeks after the first dose, average serum total IgE levels were five-fold higher compared with pre-treatment when using standard assays. After discontinuation of XOLAIR dosing, the XOLAIR-induced increase in total IgE and decrease in free IgE were reversible, with no observed rebound in IgE levels after drug washout. Total IgE levels did not return to pre-treatment levels for up to one year after discontinuation of XOLAIR.

**Nasal Polyps**

In clinical studies in nasal polyps patients, omalizumab treatment led to a reduction in serum free IgE and an increase in serum total IgE levels, similar to the observations in asthma patients. The mean total IgE concentrations at baseline were 168 IU/mL and 218 IU/mL in Nasal Polyp Trial 1 and 2, respectively. After repeated dosing every 2 or 4 weeks, with dosage and frequency according to Table 3, the mean predose free IgE concentrations at Week 16 were 10.0 IU/mL in Trial 1 and 11.7 IU/mL in Trial 2 and remained stable at 24
weeks of treatment. Total IgE levels in serum increased due to the formation of omalizumab-IgE complexes, which have a slower elimination rate compared with free IgE. After repeated dosing every 2 or 4 weeks, with dosage and frequency according to Table 3, mean and median predose serum total IgE levels at Week 16 were 3- to 4-fold higher compared with pre-treatment levels, and remained stable between 16 and 24 weeks of treatment.

**Chronic Idiopathic Urticaria**

In clinical studies in CIU patients, XOLAIR treatment led to a dose-dependent reduction of serum free IgE and an increase of serum total IgE levels, similar to the observations in asthma patients. Maximum suppression of free IgE was observed 3 days following the first subcutaneous dose. After repeat dosing once every 4 weeks, predose serum free IgE levels remained stable between 12 and 24 weeks of treatment. Total IgE levels in serum increased after the first dose due to the formation of omalizumab-IgE complexes which have a slower elimination rate compared with free IgE. After repeat dosing once every 4 weeks at 75 mg up to 300 mg, average predose serum total IgE levels at Week 12 were two- to three-fold higher compared with pre-treatment levels, and remained stable between 12 and 24 weeks of treatment. After discontinuation of XOLAIR dosing, free IgE levels increased and total IgE levels decreased towards pre-treatment levels over a 16-week follow-up period.

### 12.3 Pharmacokinetics

After SC administration, omalizumab was absorbed with an average absolute bioavailability of 62%. Following a single SC dose in adult and adolescent patients with asthma, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7–8 days. In patients with CIU, the peak serum concentration was reached at a similar time after a single SC dose. The pharmacokinetics of omalizumab was linear at doses greater than 0.5 mg/kg. In patients with asthma, following multiple doses of XOLAIR, areas under the serum concentration-time curve from Day 0 to Day 14 at steady state were up to 6-fold of those after the first dose. In patients with CIU, omalizumab exhibited linear pharmacokinetics across the dose range of 75 mg to 600 mg given as single subcutaneous dose. Following repeat dosing from 75 to 300 mg every 4 weeks, trough serum concentrations of omalizumab increased proportionally with the dose levels.

In vitro, omalizumab formed complexes of limited size with IgE. Precipitating complexes and complexes larger than 1 million daltons in molecular weight were not observed in vitro or in vivo. Tissue distribution studies in Cynomolgus monkeys showed no specific uptake of \(^{125}\text{I-omalizumab}\) by any organ or tissue. The apparent volume of distribution of omalizumab in patients with asthma following SC administration was 78 ± 32 mL/kg. In patients with CIU, based on population pharmacokinetics, distribution of omalizumab was similar to that in patients with asthma.

Clearance of omalizumab involved IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE. Liver elimination of IgG included degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG was also excreted in bile. In studies with mice and monkeys, omalizumab:IgE complexes were eliminated by interactions with Fc\(\gamma\) receptors within the RES at rates that were generally faster than IgG clearance. In asthma patients omalizumab serum elimination half-life averaged 26 days, with apparent clearance averaging 2.4 ± 1.1 mL/kg/day. Doubling body weight approximately doubled apparent clearance. In CIU patients, at steady
state, based on population pharmacokinetics, omalizumab serum elimination half-life averaged 24 days and apparent clearance averaged 240 mL/day (corresponding to 3.0 mL/kg/day for an 80 kg patient).

Specific Populations

Asthma

The population pharmacokinetics of omalizumab was analyzed to evaluate the effects of demographic characteristics in patients with asthma. Analyses of these data suggested that no dose adjustments are necessary for age (6 to 76 years), race, ethnicity, or gender.

Nasal Polyps

The population pharmacokinetics analyses of omalizumab suggested that the pharmacokinetics of omalizumab in nasal polyps were consistent with that in asthma. Graphical covariate analyses were performed to evaluate the effects of demographic characteristics and other factors on omalizumab exposure and clinical responses. These analyses demonstrate that no dose adjustments are necessary for age (18 to 75 years) or gender. Race and ethnicity data are too limited in nasal polyps studies to inform dose adjustment.

Chronic Idiopathic Urticaria

The population pharmacokinetics of omalizumab was analyzed to evaluate the effects of demographic characteristics and other factors on omalizumab exposure in patients with CIU. Covariate effects were evaluated by analyzing the relationship between omalizumab concentrations and clinical responses. These analyses demonstrate that no dose adjustments are necessary for age (12 to 75 years), race/ethnicity, gender, body weight, body mass index or baseline IgE level.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies have been performed in animals to evaluate the carcinogenic potential of XOLAIR.

There were no effects on fertility and reproductive performance in male and female Cynomolgus monkeys that received XOLAIR at subcutaneous doses up to 75 mg/kg/week (approximately 5 times the maximum recommended human dose on a mg/kg basis).

14 CLINICAL STUDIES

14.1 Asthma

Adult and Adolescent Patients 12 Years of Age and Older

The safety and efficacy of XOLAIR were evaluated in three randomized, double-blind, placebo-controlled, multicenter trials.

The trials enrolled patients 12 to 76 years old, with moderate to severe persistent (NHLBI criteria) asthma for at least one year, and a positive skin test reaction to a perennial aeroallergen. In all trials, XOLAIR dosing was based on body weight and baseline serum total IgE concentration. All patients were required to have a baseline IgE between 30 and 700 IU/mL and body weight not more than 150 kg. Patients were treated according to a dosing table to administer at least 0.016 mg/kg/IU (IgE/mL) of XOLAIR or a matching
volume of placebo over each 4-week period. The maximum XOLAIR dose per 4 weeks was 750 mg.

In all three trials an exacerbation was defined as a worsening of asthma that required treatment with systemic corticosteroids or a doubling of the baseline ICS dose. Most exacerbations were managed in the outpatient setting and the majority were treated with systemic steroids. Hospitalization rates were not significantly different between XOLAIR and placebo-treated patients; however, the overall hospitalization rate was small. Among those patients who experienced an exacerbation, the distribution of exacerbation severity was similar between treatment groups.

**Asthma Trials 1 and 2**

At screening, patients in Asthma Trials 1 and 2 had a forced expiratory volume in one second (FEV\textsubscript{1}) between 40% and 80% predicted. All patients had a FEV\textsubscript{1} improvement of at least 12% following beta\textsubscript{2}-agonist administration. All patients were symptomatic and were being treated with inhaled corticosteroids (ICS) and short acting beta\textsubscript{2}-agonists. Patients receiving other concomitant controller medications were excluded, and initiation of additional controller medications while on study was prohibited. Patients currently smoking were excluded.

Each trial was comprised of a run-in period to achieve a stable conversion to a common ICS (beclomethasone dipropionate), followed by randomization to XOLAIR or placebo. Patients received XOLAIR for 16 weeks with an unchanged corticosteroid dose unless an acute exacerbation necessitated an increase. Patients then entered an ICS reduction phase of 12 weeks during which ICS dose reduction was attempted in a step-wise manner.

The distribution of the number of asthma exacerbations per patient in each group during a study was analyzed separately for the stable steroid and steroid-reduction periods.

In both Asthma Trials 1 and 2 the number of exacerbations per patient was reduced in patients treated with XOLAIR compared with placebo (Table 9).

Measures of airflow (FEV\textsubscript{1}) and asthma symptoms were also evaluated in these trials. The clinical relevance of the treatment-associated differences is unknown. Results from the stable steroid phase Asthma Trial 1 are shown in Table 10. Results from the stable steroid phase of Asthma Trial 2 and the steroid reduction phases of both Asthma Trials 1 and 2 were similar to those presented in Table 10.
Table 9. Frequency of Asthma Exacerbations per Patient by Phase in Trials 1 and 2

<table>
<thead>
<tr>
<th>Exacerbations per patient</th>
<th>Asthma Trial 1</th>
<th>Asthma Trial 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>XOLAIR N=268</td>
<td>Placebo N=257</td>
</tr>
<tr>
<td>0</td>
<td>85.8%</td>
<td>76.7%</td>
</tr>
<tr>
<td>1</td>
<td>11.9%</td>
<td>16.7%</td>
</tr>
<tr>
<td>≥2</td>
<td>2.2%</td>
<td>6.6%</td>
</tr>
<tr>
<td>p-Value</td>
<td>0.005</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean number exacerbations/patient</td>
<td>0.2</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Steroid Reduction Phase (12 wks)

<table>
<thead>
<tr>
<th>Exacerbations per patient</th>
<th>Asthma Trial 1</th>
<th>Asthma Trial 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>XOLAIR N=268</td>
<td>Placebo N=257</td>
</tr>
<tr>
<td>0</td>
<td>78.7%</td>
<td>67.7%</td>
</tr>
<tr>
<td>1</td>
<td>19.0%</td>
<td>28.4%</td>
</tr>
<tr>
<td>≥2</td>
<td>2.2%</td>
<td>3.9%</td>
</tr>
<tr>
<td>p-Value</td>
<td>0.004</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean number exacerbations/patient</td>
<td>0.2</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Table 10. Asthma Symptoms and Pulmonary Function During Stable Steroid Phase of Trial 1

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>XOLAIR N=268*</th>
<th>Placebo N=257*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean Baseline</td>
<td>Median Change (Baseline to Wk 16)</td>
</tr>
<tr>
<td>Total asthma symptom score</td>
<td>4.3</td>
<td>−1.5†</td>
</tr>
<tr>
<td>Nocturnal asthma score</td>
<td>1.2</td>
<td>−0.4†</td>
</tr>
<tr>
<td>Daytime asthma score</td>
<td>2.3</td>
<td>−0.9†</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; % predicted</td>
<td>68</td>
<td>3†</td>
</tr>
</tbody>
</table>

Asthma symptom scale: total score from 0 (least) to 9 (most); nocturnal and daytime scores from 0 (least) to 4 (most symptoms).

* Number of patients available for analysis ranges 255-258 in the XOLAIR group and 238-239 in the placebo group.

† Comparison of XOLAIR versus placebo (p<0.05).

Asthma Trial 3

In Asthma Trial 3, there was no restriction on screening FEV<sub>1</sub>, and unlike Asthma Trials 1 and 2, long-acting beta<sub>2</sub>-agonists were allowed. Patients were receiving at least 1000 µg/day
fluticasone propionate and a subset was also receiving oral corticosteroids. Patients receiving other concomitant controller medications were excluded, and initiation of additional controller medications while on study was prohibited. Patients currently smoking were excluded.

The trial was comprised of a run-in period to achieve a stable conversion to a common ICS (fluticasone propionate), followed by randomization to XOLAIR or placebo. Patients were stratified by use of ICS-only or ICS with concomitant use of oral steroids. Patients received XOLAIR for 16 weeks with an unchanged corticosteroid dose unless an acute exacerbation necessitated an increase. Patients then entered an ICS reduction phase of 16 weeks during which ICS or oral steroid dose reduction was attempted in a step-wise manner.

The number of exacerbations in patients treated with XOLAIR was similar to that in placebo-treated patients (Table 11). The absence of an observed treatment effect may be related to differences in the patient population compared with Asthma Trials 1 and 2, study sample size, or other factors.

| Table 11. Percentage of Patients with Asthma Exacerbations by Subgroup and Phase in Trial 3 |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Stable Steroid Phase (16 wks)                | Inhaled Only | Oral + Inhaled |
| % Patients with ≥1 exacerbations             | XOLAIR N=126 | Placebo N=120 | XOLAIR N=50 | Placebo N=45 |
| Difference (95% CI)                          | 15.9%        | 15.0%        | 32.0%        | 22.2%        |
|                                            | 0.9 (–9.7, 13.7) | 9.8 (–10.5, 31.4) |
| Steroid Reduction Phase (16 wks)             | XOLAIR N=126 | Placebo N=120 | XOLAIR N=50 | Placebo N=45 |
| % Patients with ≥1 exacerbations             | 22.2%        | 26.7%        | 42.0%        | 42.2%        |
| Difference (95% CI)                          | –4.4 (–17.6, 7.4) | –0.2 (–22.4, 20.1) |

In all three of the trials, a reduction of asthma exacerbations was not observed in the XOLAIR-treated patients who had FEV\textsubscript{1}>80% at the time of randomization. Reductions in exacerbations were not seen in patients who required oral steroids as maintenance therapy.

**Pediatric Patients 6 to <12 Years of Age**

The safety and efficacy of XOLAIR in pediatric patients 6 to <12 years of age with moderate to severe asthma is based on one randomized, double-blind, placebo controlled, multi-center trial (Trial 4) and an additional supportive study (Trial 5).

Trial 4 was a 52-week study that evaluated the safety and efficacy of XOLAIR as add-on therapy in 628 pediatric patients ages 6 to <12 years with moderate to severe asthma.
inadequately controlled despite the use of inhaled corticosteroids (fluticasone propionate DPI ≥200 mcg/day or equivalent) with or without other controller asthma medications. Eligible patients were those with a diagnosis of asthma >1 year, a positive skin prick test to at least one perennial aeroallergen, and a history of clinical features such as daytime and/or night-time symptoms and exacerbations within the year prior to study entry. During the first 24 weeks of treatment, steroid doses remained constant from baseline. This was followed by a 28-week period during which inhaled corticosteroid adjustment was allowed.

The primary efficacy variable was the rate of asthma exacerbations during the 24-week, fixed steroid treatment phase. An asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids for at least 3 days. At 24 weeks, the XOLAIR group had a statistically significantly lower rate of asthma exacerbations (0.45 vs. 0.64) with an estimated rate ratio of 0.69 (95% CI: 0.53, 0.90).

The XOLAIR group also had a lower rate of asthma exacerbations compared to placebo over the full 52-week double-blind treatment period (0.78 vs. 1.36; rate ratio: 0.57; 95% CI: 0.45, 0.72). Other efficacy variables such as nocturnal symptom scores, beta-agonist use, and measures of airflow (FEV1) were not significantly different in XOLAIR-treated patients compared to placebo.

Trial 5 was a 28-week randomized, double blind, placebo-controlled study that primarily evaluated safety in 334 pediatric patients, 298 of whom were 6 to <12 years of age, with moderate to severe asthma who were well-controlled with inhaled corticosteroids (beclomethasone dipropionate 168-420 mcg/day). A 16-week steroid treatment period was followed by a 12-week steroid dose reduction period. Patients treated with XOLAIR had fewer asthma exacerbations compared to placebo during both the 16-week fixed steroid treatment period (0.18 vs. 0.32; rate ratio: 0.58; 95% CI: 0.35, 0.96) and the 28-week treatment period (0.38 vs. 0.76; rate ratio: 0.50; 95% CI: 0.36, 0.71).

14.2 Nasal Polyps

Adult Patients 18 Years of Age and Older

The safety and efficacy of XOLAIR was evaluated in two, randomized, multicenter, double-blind, placebo-controlled clinical trials that enrolled patients with nasal polyps with inadequate response to nasal corticosteroids (Nasal Polyps Trial 1, n=138; Nasal Polyps Trial 2, n=127). Patients received XOLAIR or placebo SC every 2 or 4 weeks, with XOLAIR dosage and frequency according to Table 3, for 24 weeks followed by a 4-week follow-up period. All patients received background nasal mometasone therapy during both the treatment period and during a 5-week run-in period. Prior to randomization, patients were required to have evidence of bilateral polyps as determined by a nasal polyp score (NPS) ≥ 5 with NPS ≥ 2 in each nostril, despite use of nasal mometasone during the run-in period. NPS was measured via endoscopy and scored (range 0-4 per nostril: 0=no polyps; 1=small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2=polyps reaching below the lower border of the middle turbinate; 3=large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; 4=large polyps causing complete obstruction of the inferior nasal cavity) for a total NPS (range 0-8).

Patients were furthermore required to have a weekly average of nasal congestion score
(NCS) > 1 prior to randomization, despite use of nasal mometasone. Nasal congestion was measured by a daily assessment on a 0 to 3 point severity scale (0=none, 1=mild, 2=moderate, 3=severe). Prior sino-nasal surgery or prior systemic corticosteroid usage were not required for inclusion in the trials and sinus CT scans were not performed to evaluate for sinus opacification. Demographics and baseline characteristics, including allergic comorbidities, are described in Table 12.

Table 12. Demographics and Baseline Characteristics of Nasal Polyps Trials 1 and 2

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Nasal Polyps Trial 1 (n=138)</th>
<th>Nasal Polyps Trial 2 (n=127)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years) (SD)</td>
<td>51 (13)</td>
<td>50 (12)</td>
</tr>
<tr>
<td>% Male</td>
<td>64</td>
<td>65</td>
</tr>
<tr>
<td>Patients with systemic corticosteroid use in the previous year (%)</td>
<td>19 (57)</td>
<td>26 (62)</td>
</tr>
<tr>
<td>Patients with prior surgery for nasal polyps (%)</td>
<td>79 (57)</td>
<td>79 (62)</td>
</tr>
<tr>
<td>Mean bilateral endoscopic NPS (SD), range 0-8</td>
<td>6.2 (1.0)</td>
<td>6.3 (0.9)</td>
</tr>
<tr>
<td>Mean nasal congestion score (SD) range 0-3</td>
<td>2.4 (0.6)</td>
<td>2.3 (0.7)</td>
</tr>
<tr>
<td>Mean sense of smell score (SD) range 0-3</td>
<td>2.7 (0.7)</td>
<td>2.7 (0.7)</td>
</tr>
<tr>
<td>Mean post nasal drip score (SD) range 0-3</td>
<td>1.8 (0.9)</td>
<td>1.7 (0.9)</td>
</tr>
<tr>
<td>Mean runny nose score (SD) range 0-3</td>
<td>2.0 (0.8)</td>
<td>1.9 (0.9)</td>
</tr>
<tr>
<td>Mean blood eosinophils (cells/mcL) (SD)</td>
<td>346 (284)</td>
<td>335 (188)</td>
</tr>
<tr>
<td>Mean total IgE IU/mL (SD)</td>
<td>161 (140)</td>
<td>190 (201)</td>
</tr>
<tr>
<td>Asthma (%)</td>
<td>54</td>
<td>61</td>
</tr>
<tr>
<td>Aspirin exacerbated respiratory disease (%)</td>
<td>20</td>
<td>35</td>
</tr>
</tbody>
</table>

SD=standard deviation; NPS=nasal polyp score; IgE = Immunoglobulin E; IU=international units. For NPS, NCS, sense of smell, post nasal drip, and runny nose, higher scores indicate greater disease severity.

The co-primary endpoints in Trials 1 and 2 were NPS and average daily NCS at Week 24. In both trials, patients who received XOLAIR had a statistically significant greater improvement from baseline at Week 24 in NPS and weekly average NCS, than patients who received placebo. Results from Nasal Polyps Trials 1 and 2 are shown in Table 13.

The greater improvements in NPS and NCS in the XOLAIR group compared to the placebo group were observed as early as the first assessment at Week 4 in both studies, as seen in Figure 1.

Table 13. Change from Baseline at Week 24 in Nasal Polyp Score and 7-day Average of Daily Nasal Congestion Score in Nasal Polyps Trials 1 and 2

<table>
<thead>
<tr>
<th>Trial 1</th>
<th>Trial 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>XOLAIR</td>
</tr>
<tr>
<td>Placebo</td>
<td>XOLAIR</td>
</tr>
</tbody>
</table>

33
<table>
<thead>
<tr>
<th></th>
<th>Trial 1</th>
<th>Trial 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>XOLAIR</td>
</tr>
<tr>
<td>Number of patients</td>
<td>65</td>
<td>72</td>
</tr>
<tr>
<td>Nasal Polyp Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Baseline Score</td>
<td>6.3</td>
<td>6.2</td>
</tr>
<tr>
<td>LS Mean Change From Baseline at Week 24</td>
<td>0.1</td>
<td>-1.1</td>
</tr>
<tr>
<td>Difference in LS means vs. placebo</td>
<td>-1.1</td>
<td>-0.6</td>
</tr>
<tr>
<td>95% CI for difference</td>
<td>-1.6, -0.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-day Average of Daily Nasal Congestion Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Baseline Score</td>
<td>2.5</td>
<td>2.4</td>
</tr>
<tr>
<td>LS Mean Change From Baseline at Week 24</td>
<td>-0.4</td>
<td>-0.9</td>
</tr>
<tr>
<td>Difference in LS means vs. placebo</td>
<td>-0.6</td>
<td>-0.5</td>
</tr>
<tr>
<td>95% CI for difference</td>
<td>-0.8, -0.3</td>
<td>0.0004</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LS=least-square. Change from baseline was analyzed using a mixed-effect model of repeated measures (MMRM) model with baseline score, baseline score/timepoint (week) interaction as covariates, and the following factors: geographic region, asthma/aspirin sensitivity comorbidity status, timepoint, treatment group, treatment/timepoint interaction.

The mean NPS and NCS at each study week by treatment group is shown in Figure 1.
XOLAIR had statistically significant improvements on sense of smell score compared to placebo. Sense of smell was measured by a daily assessment on a 0 to 3 point severity scale (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms). The LS mean difference for change from baseline at Week 24 in sense of smell score in XOLAIR compared to placebo was -0.3 (95% CI: -0.6, -0.1) in Trial 1 and -0.5 (95% CI: -0.7, -0.2) in Trial 2.

XOLAIR had statistically significant improvements on post-nasal drip compared to placebo. The LS mean difference for change from baseline at Week 24 in post-nasal drip score in XOLAIR compared to placebo was -0.6 (95% CI: -0.8, -0.3) in Trial 1 and -0.5 (95% CI: -0.8, -0.3) in Trial 2.

XOLAIR had statistically significant improvements on runny nose compared to placebo. The LS mean difference for change from baseline at Week 24 in runny nose score in XOLAIR compared to placebo was -0.4 (95% CI: -0.7, -0.2) in Trial 1 and -0.6 (95% CI: -0.9, -0.4) in Trial 2.

In a pre-specified pooled analysis of systemic corticosteroid use during the 24-week treatment period, there was no significant reduction in systemic corticosteroid use between the treatment arms. The proportion of patients taking systemic corticosteroid in XOLAIR was 2.3% compared to 6.2% in placebo. The odds-ratio of systemic corticosteroid use with XOLAIR compared to placebo was 0.4 (95% CI: 0.1, 1.5).

There were no sino-nasal surgeries reported, in either placebo or XOLAIR arms, in either Trial.
14.3 Chronic Idiopathic Urticaria
Adult and Adolescent Patients 12 Years of Age and Older

The safety and efficacy of XOLAIR for the treatment of CIU was assessed in two placebo-controlled, multiple-dose clinical trials of 24 weeks’ duration (CIU Trial 1; n= 319) and 12 weeks’ duration (CIU Trial 2; n=322). Patients received XOLAIR 75 mg, 150 mg, or 300 mg or placebo by SC injection every 4 weeks in addition to their baseline level of H1 antihistamine therapy for 24 or 12 weeks, followed by a 16-week washout observation period. A total of 640 patients (165 males, 475 females) were included for the efficacy analyses. Most patients were white (84%) and the median age was 42 years (range 12–72).

Disease severity was measured by a weekly urticaria activity score (UAS7, range 0–42), which is a composite of the weekly itch severity score (range 0–21) and the weekly hive count score (range 0–21). All patients were required to have a UAS7 of ≥16, and a weekly itch severity score of ≥8 for the 7 days prior to randomization, despite having used an H1 antihistamine for at least 2 weeks.

The mean weekly itch severity scores at baseline were fairly balanced across treatment groups and ranged between 13.7 and 14.5 despite use of an H1 antihistamine at an approved dose. The reported median durations of CIU at enrollment across treatment groups were between 2.5 and 3.9 years (with an overall subject-level range of 0.5 to 66.4 years).

In both CIU Trials 1 and 2, patients who received XOLAIR 150 mg or 300 mg had greater decreases from baseline in weekly itch severity scores and weekly hive count scores than placebo at Week 12. Representative results from CIU Trial 1 are shown (Table 14); similar results were observed in CIU Trial 2. The 75-mg dose did not demonstrate consistent evidence of efficacy and is not approved for use.
Table 14. Change from Baseline to Week 12 in Weekly Itch Severity Score and Weekly Hive Count Score in CIU Trial 1 *

<table>
<thead>
<tr>
<th></th>
<th>XOLAIR 75mg</th>
<th>XOLAIR 150mg</th>
<th>XOLAIR 300mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>77</td>
<td>80</td>
<td>81</td>
<td>80</td>
</tr>
<tr>
<td>Mean Baseline Score (SD)</td>
<td>14.5 (3.6)</td>
<td>14.1 (3.8)</td>
<td>14.2 (3.3)</td>
<td>14.4 (3.5)</td>
</tr>
<tr>
<td>Mean Change Week 12 (SD)</td>
<td>−6.46 (6.14)</td>
<td>−6.66 (6.28)</td>
<td>−9.40 (5.73)</td>
<td>−3.63 (5.22)</td>
</tr>
<tr>
<td>Difference in LS means vs. placebo</td>
<td>−2.96</td>
<td>−2.95</td>
<td>−5.80</td>
<td></td>
</tr>
<tr>
<td>95% CI for difference</td>
<td>−4.71, −1.21</td>
<td>−4.72, −1.18</td>
<td>−7.49, −4.10</td>
<td></td>
</tr>
<tr>
<td>Mean Baseline Score (SD)</td>
<td>17.2 (4.2)</td>
<td>16.2 (4.6)</td>
<td>17.1 (3.8)</td>
<td>16.7 (4.4)</td>
</tr>
<tr>
<td>Mean Change Week 12 (SD)</td>
<td>−7.36 (7.52)</td>
<td>−7.78 (7.08)</td>
<td>−11.35 (7.25)</td>
<td>−4.37 (6.60)</td>
</tr>
<tr>
<td>Difference in LS means vs. placebo</td>
<td>−2.75</td>
<td>−3.44</td>
<td>−6.93</td>
<td></td>
</tr>
<tr>
<td>95% CI for difference</td>
<td>−4.95, −0.54</td>
<td>−5.57, −1.32</td>
<td>−9.10, −4.76</td>
<td></td>
</tr>
</tbody>
</table>

* Modified intent-to-treat (mITT) population: all patients who were randomized and received at least one dose of study medication.

† Score measured on a range of 0–21

The mean weekly itch severity score at each study week by treatment groups is shown in Figure 2. Representative results from CIU Trial 1 are shown; similar results were observed in CIU Trial 2. The appropriate duration of therapy for CIU with XOLAIR has not been determined.

**Figure 2. Mean Weekly Itch Severity Score by Treatment Group Modified Intent to Treat Patients in CIU Trial 1**
In CIU Trial 1, a larger proportion of patients treated with XOLAIR 300 mg (36%) reported no itch and no hives (UAS7=0) at Week 12 compared to patients treated with XOLAIR 150 mg (15%), XOLAIR 75 mg (12%), and placebo group (9%). Similar results were observed in CIU Trial 2.

16 HOW SUPPLIED/STORAGE AND HANDLING

Injection (Prefilled Syringe)

XOLAIR (omalizumab) injection is a clear to slightly opalescent and colorless to pale brownish-yellow solution in a single-dose prefilled glass syringe with a 26 gauge staked needle, rigid needle cap, and needle shield. Each carton contains one prefilled syringe.

Each XOLAIR 75 mg carton contains one single-dose 75 mg prefilled syringe with a blue needle shield (NDC 50242-214-01).

Each XOLAIR 150 mg carton contains one single-dose 150 mg prefilled syringe with a purple needle shield (NDC 50242-215-01).

XOLAIR prefilled syringe should be shipped and stored under refrigerated conditions 2°C to 8°C (36°F to 46°F) in the original carton. Protect from direct sunlight. Do not freeze. Do not use if the syringe has been frozen.

For Injection (Vial)

XOLAIR is supplied as a lyophilized, white, sterile powder in a single-dose vial without preservatives. Each carton contains one 150 mg single-dose vial of XOLAIR® (omalizumab) for injection NDC 50242-040-62.

XOLAIR should be shipped at controlled ambient temperature (≤30°C [≤86°F]). Store XOLAIR under refrigerated conditions 2°C to 8°C (36°F to 46°F) in the original carton. Do not use beyond the expiration date stamped on carton.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Information for Patients

Provide and instruct patients to read the accompanying Medication Guide before starting treatment and before each subsequent treatment. The complete text of the Medication Guide is reprinted at the end of this document.

Inform patients of the risk of life-threatening anaphylaxis with XOLAIR including the following points [see Boxed Warning and Warnings and Precautions (5.1)]:

- There have been reports of anaphylaxis occurring up to 4 days after administration of XOLAIR
- XOLAIR should only be administered in a healthcare setting by healthcare providers
- Patients should be closely observed following administration
- Patients should be informed of the signs and symptoms of anaphylaxis
- Patients should be instructed to seek immediate medical care should such signs or symptoms occur

Instruct patients receiving XOLAIR not to decrease the dose of, or stop taking any other asthma, nasal polyps, or CIU medications unless otherwise instructed by their physician.
Inform patients that they may not see immediate improvement in their asthma, nasal polyps, or CIU symptoms after beginning XOLAIR therapy.

Inform patients the needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.

Manufactured by:
**Genentech, Inc.**
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080-4990
U.S. License No.:1048
**MEDICATION GUIDE**

**XOLAIR® (ZOHL-air)**
(omalizumab)

**injection, for subcutaneous use**

---

**What is the most important information I should know about XOLAIR?**

**XOLAIR may cause serious side effects, including:**

**Severe allergic reaction.** A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

- wheezing, shortness of breath, cough, chest tightness, or trouble breathing
- low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
- flushing, itching, hives, or feeling warm
- swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider’s office or treatment center.

**What is XOLAIR?**

XOLAIR is an injectable prescription medicine used to treat:

- moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not controlled with their current asthma medicines. XOLAIR helps prevent severe asthma attacks (exacerbations). A skin or blood test is performed to see if you have allergies to year-round allergens.
- nasal polyps in people 18 years of age and older when medicines to treat nasal polyps called nasal corticosteroids have not worked well enough. It is not known if XOLAIR is safe and effective in people with nasal polyps under 18 years of age.
- chronic idiopathic urticaria (CIU, chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with their current CIU medicines.

XOLAIR is not used to treat other allergic conditions, other forms of hives, or sudden breathing problems.

**Who should not receive XOLAIR?**

**Do not receive XOLAIR if you:**

- are allergic to omalizumab or any of the ingredients in XOLAIR. See the end of this Medication Guide for a complete list of ingredients in XOLAIR.

**What should I tell my healthcare provider before receiving XOLAIR?**

**Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:**

- have a latex allergy or any other allergies (such as food allergy or seasonal allergies). The needle cap on the XOLAIR prefilled syringe may contain latex.
- have sudden breathing problems (bronchospasm)
- have ever had a severe allergic reaction called anaphylaxis
- have or have had a parasitic infection
- have or have had cancer
- are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive XOLAIR.

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, or herbal supplements.

**How should I receive XOLAIR?**
• XOLAIR should be given by your healthcare provider in a healthcare setting.
• XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.
• In people with asthma and nasal polyps, a blood test for a substance called IgE must be performed prior to starting XOLAIR to determine the appropriate dose and dosing frequency.
• In people with chronic hives, a blood test is not necessary to determine the dose or dosing frequency.
• Do not decrease or stop taking any of your other asthma, nasal polyps, or hive medicine unless your healthcare providers tell you to.
• You may not see improvement in your symptoms right away after XOLAIR treatment.

What are the possible side effects of XOLAIR?
XOLAIR may cause serious side effects, including:
• See “What is the most important information I should know about XOLAIR?”
• Cancer. Cases of cancer were observed in some people who received XOLAIR.
• Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive XOLAIR. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by XOLAIR. Tell your healthcare provider right away if you have:
  o rash
  o shortness of breath
  o chest pain
  o a feeling of pins and needles or numbness of your arms or legs
• Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
• Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
• Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether these are caused by XOLAIR.

The most common side effects of XOLAIR:
• In adults and children 12 years of age and older with asthma: pain especially in your arms and legs, dizziness, feeling tired, skin rash, bone fractures, and pain or discomfort of your ears.
• In children 6 to less than 12 years of age with asthma: common cold symptoms, headache, fever, sore throat, pain or discomfort of your ear, abdominal pain, nausea, vomiting and nose bleeds.
• In adults with nasal polyps: headache, injection site reactions, joint pain, upper abdominal pain, and dizziness.
• In people with chronic idiopathic urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection.
• These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of XOLAIR.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information, talk to your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about XOLAIR that is written for health professionals. Do not use XOLAIR for a condition for which it was not prescribed.
For more information, go to www.xolair.com or call 1-866-4XOLAIR (1-866-496-5247).

What are the ingredients in XOLAIR?
Active ingredient: omalizumab
Inactive ingredients:
Prefilled syringe: L-arginine hydrochloride, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20
Vial: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20 and sucrose
Manufactured by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. U.S. License No.: 1048
Jointly marketed by:
Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080
XOLAIR® is a registered trademark of Novartis AG. ©2020 Genentech USA, Inc.
This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 11/2020